

Overview

Poster sessions are designed to give presenters an opportunity to discuss informally their research with colleagues interested in their research. The purpose of the posters is to visually stimulate interest in the research, to present sufficient information for viewers to understand the methods, results, and significance of the research, and to promote conversations and networking among conference participants.

Note: Neither ISPE nor the Hilton will be responsible for any poster that is left up overnight or is lost or damaged.

Poster Session

Posters will be displayed in the Durham Room of the Hilton Metropole, August 20-22. Each day will have a separate poster session. All posters for a specific day's session must be removed that day.

- * **Friday, August 20**Poster Session A
- * **Saturday, August 21**Poster Session B
- * **Sunday, August 22**Poster Session C

1. Set Up:

- * 7:00am-8:00am; all posters must be in place by 8:00am. The poster sessions will be held in the Durham Room and Exhibit Hall 7.

2. Hours:

- * Posters will be displayed from 7:30am-6:00pm on Friday; 8:00am-6:00pm on Saturday, and 8:00am-1:45pm on Sunday.

3. Discussion Time:

- * **General:** Presenters should be at their posters between 12:15-1:15pm.
- * **Poster Walks:** organized by the ISPE Special Interest Groups (SIG).
Saturday, August 21, 12:45-1:30pm. Poster walks offer pre-selected presenters the opportunity to present their work and to discuss their results with an audience.

There will be poster walks for:

- | | |
|--|--|
| -Biologics | - Databases |
| -Drug Utilization/Health Services Research | - Medicines in Pregnancy |
| -Comparative Effectiveness Research | - Molecular Epidemiology/
Biomarkers/Pharmacogenetics |

Poster walk presenter:

- Be at your poster 12:45-1:30pm
- When the poster walk chair and audience stop at your poster, please give a brief, 3-minutes and be prepared to answer questions about your research.

Poster Prizes:

- A group of judges will select the best posters of each poster walk. The best presenters will receive an invitation to display their poster for the duration of the ICPE. The best posters will be announced and prizes awarded during The Final Session at 4:30pm, August 22.

4. Take Down:

- All posters must be taken down by 6:30pm on Friday and Saturday, and by 5:00pm on Sunday.

Numbering System

- * Each poster board will be numbered. Presenters should attach their posters to the board number corresponding to the number assigned to their poster in the **Final Program**, which will be available at the ISPE Registration Desk (Sussex Lounge). The poster number is the first number listed. Please note the number may differ from that shown in the preliminary program. The abstract number, for use in locating abstracts in the **Final Program** and the special issue of *Pharmacoepidemiology and Drug Safety*, is in brackets [] after the title of the abstract.

Poster Specifications

1. Posters must be designed to fit a free-standing poster board **3 feet WIDE x 5 feet HIGH (90 cm wide x 150 cm high) PORTRAIT**. Posters may be mounted using Velcro tape; please bring your own supplies. Business cards or small leaflet literature for distribution may be inserted in an envelope and affixed to the board.
2. Posters may be attached to the boards using Velcro. All poster presenters are encouraged to bring their own supplies.
3. **Disclosure Statement**
A disclosure statement must accompany each abstract submission and each presentation. This statement must list all funding sources for the current project, as well as other potentially conflicting relationships that existed at any time during the conduct of the study, or at a minimum, the one-year period before ICPE 2010. Non-financial conflicts (e.g., a close relationship with, or a strong antipathy to, a person whose interests may be affected) should also be disclosed. Potential conflicts must be listed on the poster in a type size consistent with the rest of the poster.

Anti-Infectives

- 1 **Describing Antimicrobial Use among Inpatients Infected with Methicillin-Resistant Staphylococcus aureus (MRSA) [43]**
Aisling R Caffrey, Brian J Quilliam, Kerry L LaPlante. (United States)
- 2 **Safety and Rationale of Antimicrobial Fixed Dose Combinations Marketed in Latin American Countries [44]**
Veronika J Wirtz, Jonneke Verdijk, Katja Taxis. (Mexico)
- 3 **Antibiotic Use: Main Indications and Their Therapies [45]**
Ria Benko, Maria Matuz, Edit Hajdu, Peter Doro, Gyongyver Soos. (Hungary)
- 4 **Characteristics of Inpatient Antibacterial Use in Hungary (1996-2007) [46]**
Ria Benko, Maria Matuz, Edit Hajdu, Reka Viola, Gyongyver Soos. (Hungary)
- 5 **Trends in Systemic Antibiotic Prescribing for Children in Ireland [47]**
C Keogh, U Reulbach, K Bennett, T Fahey. (Ireland)

Blood

- 6 **Utilization of Antithrombotic Agents after Major Orthopedic Surgeries in Southern Taiwan [48]**
Yu-Ying Yu, Li-Chia Chen, Hsueh-Er Chan, Jin-Song Wu. (Taiwan)
- 7 **Total Cholesterol Concentration Reductions with Statin Treatment in Chronic Disease Patients [49]**
Xia Sheng, Li Wei, Thomas M MacDonald. (United Kingdom)
- 8 **Use of Non-Steroidal Anti-Inflammatory Drugs and Risk of Re-Operation Due to Bleeding after Breast Cancer Surgery: A Danish Population Based Cohort Study [50]**
Deirdre Cronin-Fenton, Timothy L Lash, Heidi Hundborg, Henrik T Sørensen. (Denmark)
- 9 **Phenprocoumon Exposure and Risk of Intracerebral Bleeding [51]**
Sigrid Behr, Frank Andersohn, Edeltraut Garbe. (Germany)
- 10 **Persistence and Adherence to Antiplatelet Regimens in the Tayside Stroke Cohort [52]**
Robert W Flynn, Thomas M MacDonald, Gordon D Murray, Ronald S MacWalter, Alexander S Doney. (United Kingdom)

- 11 **Cardiovascular Drug Use in Patients Hospitalized with a First-Time Myocardial Infarction in Sweden [53]**
Andrijs Leimanis, Michael Fored, Niklas Hammar, Helena Schiöler, Björn Wettermark. (Sweden)
- 12 **Risk of Subarachnoid Hemorrhage Associated with Outpatient Anticoagulant Use [54]**
Sigrid Behr, Edeltraut Garbe. (Germany)
- 13 **Analysis of Aranesp Patient Exposure for Cancer Indications Using 2 Existing Databases [55]**
Fei Xue, David Quach, Greg Hess, Daniel Blaney, Julie Moloney, Victor Gastanaga, Jason Yuan, Scott Stryker, Gail Hughes, Cristina Damatarca, Sean Zhao. (United States)
- 14 **Effectiveness and Safety of Prophylactic Antithrombotic Agents after Major Orthopedic Surgeries in Southern Taiwan [56]**
Li-Chia Chen, Yu-Ying Yu, Hsueh-Er Chan, Jin-Song Wu. (Taiwan)

Cancer and Immunity

- 15 **Gastrointestinal Perforation (GIP), Fistula, and Abscess among Ovarian Cancer Patients [57]**
Michael Taylor, Wei Dong, Laura Chu. (United States)
- 16 **Interstitial Lung Disease (ILD) in Gefitinib-Treated Japanese Patients with Non-Small Cell Lung Cancer (NSCLC): Genome-Wide Analysis of Genetic Data [58]**
Fredrik Nyberg, Bryan Barratt, Yusuke Nakamura, Naoyuki Kamatani. (Sweden)
- 17 **Adverse Drug Reactions Induced by Antineoplastic Agents in Hospitalized Patients [59]**
Kheirollah Gholami, Mahdieh Fazlollahi, Sanambar Sadighi, Gloria Shalviri. (Islamic Republic of Iran)
- 18 **Risk of Lung Cancer in Users of Estradiol/Dydrogesterone or Other HRT Preparations [60]**
Cornelia Schneider, Susan S Jick, Christoph R Meier. (Switzerland)
- 19 **Osteoporosis and Esophageal Cancer [61]**
Bharat T Thakrar, Cees Schep, Alan Nevitt, Noah J Robinson. (Switzerland)
- 20 **Hip/Knee Arthroplasty and Risk of Hip Fracture: A Population-Based Case-Control Study [62]**
Arief Lalmohamed, Nigel Arden, Tjeerd P van Staa, Hubertus GM Leufkens, Frank de Vries. (Netherlands)

- 21 **Long Term Clinical Outcomes of Patients with Adult Chronic Immune Thrombocytopenic Purpura (cITP) [63]**
Mette Nørgaard, Annette Østergaard Jensen, Malene Cramer Engebjerg, Sean Zhao, Henrik Toft Sørensen. (Denmark)
- 22 **Effectiveness and Safety of Bevacizumab (BV)+FOLFIRI as 1st-Line Metastatic Colorectal Cancer (mCRC) Treatment: ETNA Cohort Study [64]**
A Fourrier-Reglat, M Rouyer, J Benichou, A Balestra, M A Bernard, A Grelaud, D Smith, A Ravaud, N Moore, and the ETNA Group. (France)
- 23 **Cardiotoxicity and Other Adverse Events Associated with Mitoxantrone Treatment for Multiple Sclerosis [65]**
Elaine Kingwell, Marcus Koch, Bonnie Leung, Saul Isserow, Jane Geddes, Peter Rieckmann, Helen Tremlett. (Canada)

Cardiovascular

- 24 **Epidemiology of Venous Thromboembolism Following Knee Replacement Surgery in the Taiwanese Population — A Ten-Year Nationwide Experience [66]**
Yea-Huei Kao Yang, Cheng-Han Lee, Ching-Lan Cheng, Chyun-Yu Yang, Li-Jen Lin, Tzu-Chieh Lin, Chia-Hsien Chang. (Taiwan)
- 25 **Relationship between Statin-Associated Total Cholesterol Concentration Change and Cardiovascular Outcome among Diabetes Patients: A Population-Based Cohort Study [67]**
Xia Sheng, Li Wei, Thomas M MacDonald. (United Kingdom)
- 26 **Abstract Withdrawn by Author [68]**
- 27 **Utilization of a Computer-Based Reminder To Improve Surveillance of the Antipsychotic-Related Risk of Arrhythmia in a Teaching Hospital [69]**
Jean Frederic Westphal, Cathy Nonnenmacher. (France)
- 28 **EARTH – Epidemiology of Athero-sclerotic Disease in The UK: Evidence of Reducing Incidence of Cardiovascular Disease (CVD), Particularly Coronary Heart Disease, in the UK Adult Population between 1999 and 2008 [70]**
Anna Shafe, Sally Lee, Martin Cowie. (United Kingdom)

- 29 Risk Profile and OC Utilization Patterns of Women Enrolled in INAS-Score [71]**
Kristina Bardenheuer, Clare A Barnett, Juergen Dinger, Christian Franke. (Germany)
- 30 Compliance with Antihypertensive Agents and the Onset of End-Stage Renal Disease [72]**
Miriam Lessard, Louise Roy, Alice Dragomir, Sylvie Perreault. (Canada)
- 31 The Safety of Oral Hormone Replacement Therapy: Interim Results from the EURAS-HRT Study [73]**
Anita Assmann, Klaas Heinemann, Juergen Dinger. (Germany)
- 32 Trends in Statin Prescription in the UK 2002-2008 – Demographics and Determinants of Non-Adherence [74]**
Jakob Petersen, David Irvine, Lesley Wise. (United Kingdom)
- 33 Abstract Withdrawn by Author [75]**
- 34 Prescription Trends for Dopamine Agonists in UK Primary Care – The Influence of Safety Alerts Concerning Valvular Heart Disease [76]**
René Schade, Jeanne P Dieleman, Miriam C Sturkenboom. (Netherlands)
- 35 Aspirin Use in Elderly with Type 2 Diabetes: Effects on Myocardial Infarction and Gastro-Intestinal Bleeding [77]**
Caroline Sirois, Jocelyne Moisan, Jean-Pierre Grégoire. (Canada)
- 36 Cohort Description of the Drug-Induced Arrhythmia Risk Evaluation (DARE) Study [78]**
Vanessa Marshall, Elijah Behr, Victoria Cornelius, Saad Shakir, John Camm. (United Kingdom)
- 37 Prescribing Patterns of Antihypertensive Drugs in 78000 Incident Users [79]**
Randi Selmer, Hege S Blix, Knud Landmark, Aasmund Reikvam. (Norway)
- 38 Discontinuation Rates of Statins Vary If Different Calculation Methods Are Used [80]**
Harm CJ Geers, Marcel L Bouvy, Rob Heerdink. (Netherlands)
- 39 Comparison of Cardiovascular Risk Factors and Survival in Patients with Ischemic or Hemorrhagic Stroke [81]**
Karin M Henriksson, Bahman Frahmmand, Signild Åsberg, Nils Edvardsson, Andreas Terént. (Sweden)
- 40 Comparison of Discontinuation of Pioglitazone Versus Rosiglitazone Utilization after Discordant Safety Concerns [82]**
Cat N Bui, Paul Godley, James Wilson, Karen Rascati. (United States)
- 41 A Randomized Controlled Trial of the Effect of a Pharmaceutical Care Program on Improving Adherence to Statin Therapy: The STatin Intervention Research Project (STIPT) [83]**
Simone Eussen, Menno van der Elst, Olaf Klungel, Cathy Rompelberg, Johan Garssen, Marco Oosterveld, Anthonius de Boer, Johan de Gier, Marcel Bouvy. (Netherlands)



**Bring
Science
to Action**

LA-SER Europe
 20 Manchester Square
 London W1U 3PZ
 United Kingdom
 Tel: +44 (0)20 3137 5800

Information on the LA-SER booth:

- PGRx systematic case-control information system
- Multipurpose cohort studies for relative benefit/risk assessment
- Patient Reported Outcomes and Use of Drugs capabilities

**ALSO IN POSTER AND ORAL PRESENTATIONS
 DURING THE MEETING**

www.la-ser.com

London – Paris – Montreal – Milan – Frankfurt – Barcelona

- 42 Regional Variation in Use of Secondary Prevention Medications among Medicare Part D Enrollees after an Acute Myocardial Infarction [84]**
Nancy E Morden, Gergory A Roth, Weiping Zhou, Jonathan A Skinner. (United States)
- 43 Prevalence of Concomitant Use of Statins with CYP 3A4 Inhibitors in Korean Elderly Outpatients [85]**
Bo Ram Yang, Nam-Kyong Choi, Ju-Young Shin, Jong-Mi Seong, Ye-Jee Kim, So-Hyeon Ahn, Mi-Sook Kim, Joongyub Lee, Byung-Joo Park. (Republic of Korea)
- 44 Medication Non-Adherence Affects Treatment Intensification for Hyperglycaemia but Not for Hypertension [86]**
Petra Denig, Jaco Voorham, Bruce HR Wolffenbuttel, Ronald P Stolk, Flora M Haaijer-Ruskamp. (Netherlands)
- 45 Abstract Withdrawn by Author [87]**
- 46 Recruitment Strategy for Genetic Data Collection: The UK General Practice Research Database [88]**
Efrosini Setakis, Frank de Vries, Munir Pirmohamed, Tjeerd-Pieter van Staa. (United Kingdom)
- 47 Using Laboratory Data To Supplement Claims Data To Improve Control of Confounding in Studies of Treatment Effects [89]**
S Schneeweiss, JA Rassen, J Avorn, DH Solomon, SY Kim, G Daniel, KJ Rothman, J Liu, RJ Glynn. (United States)
- 48 Risk of Circulatory Disorders among Patients with Asthma in a Large Integrated Health Care Delivery System [90]**
Carlos Iribarren, Irina Tolstykh, Mary K Miller, Mark D Eisner. (United States)

Classical Pharmacoepidemiology

- 49 Statistical Models for the Comparison of the Average Per-Patient Cost of Lower Limb Osteoarthritis with or without Spa Therapy [91]**
P Blin, C Toussaint, R Lassalle, S Lignot, F Hamoud, A Abouelfath, J Benichou, JL Demeaux, C Garreau, C Ohayon-Courtes, T Schaefferbeke, M Vray, N Moore. (France)
- 50 Drugs Inducing DRESS (Drug Reaction with Eosinophilia and Systemic Symptoms): The RegiSCAR Experience [92]**
Sylvia H Kardaun, Peggy Sekula, Maja Mockenhaupt, Jean-Claude Roujeau. (Netherlands)

- 51 Estimating Clopidogrel Bisulfate Use in a Pediatric Population [93]**
S Phillips, A Meyers, A Gomez, F Ernst, M Ulcickas Yood, S Oliveria. (United States)
- 52 Lymphoma Case Ascertainment in the US Pharmetrics Database [94]**
Eulogio Conde, Charles W Wentworth, Elena Rivero, Alejandro Arana. (Spain)
- 53 Serum Sodium Concentration Monitoring and Hyponatremia in Thiazide-Treated Patients [95]**
Sarah E McDowell, Jamie J Coleman, Stephen JW Evans, Robin E Ferner. (United Kingdom)
- 54 Generic Substitution in a Cohort of Swedish Patients with Heart Failure [96]**
Chamlin Nouri, Björn Wettermark, Morten Andersen, Anders Sundström, Karin Söderberg, Ulf Bergman. (Sweden)
- 55 Body Mass Index and the Incidence of Influenza-Associated Complications in a UK Population [97]**
William A Blumentals, Alan Nevitt, Liping Huang, Michael M Peng, Stephen Toovey. (United States)
- 56 Drug Utilization in Paediatric Hospitals: An International Perspective [98]**
Asia Rashed, Kenneth Lee, Noel Cranswick, Steve Tomlin, Wolfgang Rascher, Ian Wong, Antje Neubert. (United Kingdom)
- 57 Drug-Drug Interactions: Theoretical or Clinically Relevant? [99]**
Gabriella Martha, Peter Doro, Ria Benko, Iona Higyan, Maria Matuz, Gyongyver Soos. (Hungary)
- 58 Comprehensive Survival Analysis of a Cohort of Patients with Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN) [100]**
Peggy Sekula, Yvonne Liss, Sylvia H Kardaun, Jean-Claude Roujeau, for the RegiSCAR-Study Group. (Germany)
- 59 Risk of Hepatotoxicity-Related Hospitalizations among Patients Treated with Opioid/Acetaminophen Combination Prescription Pain Medications [101]**
Mei-Sheng Duh, Francis Vekeman, Caroline Korves, Patrick Lefebvre, Ellison Dial, Dominick Latremouille-Viau, Robert S Wei, Bruce E Stangle, Marie-Helene Lafeuille, Edward Michna, Paul E Greenberg. (United States)

CNS

- 60 High Degree of Co-Medication of Benzodiazepines in Norway [102]**
Marte Handal, Svetlana Skurtveit, Jørg G Mørland. (Norway)
- 61 A Comparison of Opioid Use Patterns in Medicare, Medicaid, and a National Prescription Tracker Service [103]**
Fatmatta Kuyateh, Hina Mehta, Rita Ouellet-Hellstrom, Farzana Ali, Emily Singer, Thomas E MaCurdy, David J Graham. (United States)
- 62 Patterns and Predictors of Pharmacotherapy after Hospitalization for Major Depression [105]**
Jennifer Lund, Stacie Dusetzina, Bradley Gaynes, Richard Hansen, Michele Jonsson Funk. (United States)
- 63 Patients' Value of Benefits and Harms of Migraine Treatments [106]**
Paul M Coplan, Brett A Hauber, Ateasha Mohamed, Reed F Johnson, Bennett Levitan. (United States)
- 64 Antiepileptic Drug Use during Pregnancy: Perinatal Outcomes with Monotherapy, Polytherapy, or Discontinuation of Treatment [107]**
Sophie Kulaga, Odile Sheehy, Amir Zargarzadeh, Anick Bérard. (Canada)
- 65 Accuracy of Reporting and Method for Classifying Progressive Multifocal Leukoencephalopathy (PML) within the FDA Adverse Event Reporting System (AERS) [108]**
Anokhi J Kapasi, Bao-Anh Nguyen-Khoa, Earl L Goehring, Jr, Kimberly Alexander, Pavel K Napalkov, Nadia Foskett, Judith K Jones. (United States)
- 66 Can Pharmacoethnicity Be Studied in Spontaneous Reports? The Example of Vincristine Neurotoxicity [109]**
M Hauben, M Younus, A Bate. (United States)
- 67 Analysis of Aripiprazole Utilisation from Prescription-Event Monitoring (PEM): Focus on Off Label Use in Support of Risk Management [110]**
Vicki Osborne, Deborah Layton, Saad AW Shakir. (United Kingdom)

- 68 Prescribed Antipsychotic Drugs and Risk of Re-Hospitalization among Incident Patients with Schizophrenia-Related Diagnosis [111]**
Olof Stephansson, Johan Reutfors, Lena Brandt, Helle Kieler. (Sweden)
- 69 Co-Prescribing of Medications with Anticholinergic Properties to Those Using Cholinesterase Inhibitors for Dementia [112]**
Katherine Bloomfield, Nick John, Anita McGrogan, Roy Jones, Corinne de Vries. (United Kingdom)
- 70 Overdose Deaths in Relation to Filled Prescriptions with Methadone, Subutex and Suboxone [113]**
Helle Kieler, Lena Brandt, Henrik Druid, Johan Franck, Olof Stephansson. (Sweden)
- 71 The Impact of Regulatory Action on ECG Monitoring in Patients with Dopamine Agonists in Japan: Analysis of Claims Database [114]**
Nobuhiro Ooba, Takuhiro Yamaguchi, Kiyoshi Kubota. (Japan)
- 72 Risk of Falls in the Elderly Population Using Antipsychotics: A Systematic Review [115]**
Sarah-Gabrielle Beland, Anne-Marie Cloutier, Camille Craig, Michel Preville, Yola Moride. (Canada)
- 73 Factors Associated with Adherence and Persistency to Antidepressants in Korea [117]**
Sun-Young Jung, HyunJin Song, Sangjin Shin, Eunhee Shin, JooYeon Park, Jeonghoon Ahn. (Republic of Korea)
- 74 Heterogeneity in Drug Utilization in Three European Countries: A Study of Dopamine Agonists [658]**
Cynthia de Luise, Gianluca Trifirò, Mostafa Mokhles, Jeanne Dieleman, Eva van Soest, Giampiero Mazzaglia, Ron Herings, Doug Ross, Miriam Sturkenboom. (United States)

*Drug Utilization Research/
Health Services Research*

- 75 Abstract Withdrawn by Author [118]**
- 76 Hormone Replacement Therapy Prescription in France [119]**
Florence Gass, Christine Damase-Michel, Caroline Hurault, Robert Bourrel, Jean Louis Montastruc. (France)
- 77 Medication Usage and Prominent Predictors of High Level Polypharmacy in Hospitalized Indian Elderly: A Study from Two Tertiary Care Hospitals [120]**
Gurumurthy Parthasarathi, Anand Harugeri, Madhan Ramesh, Shoba Guido. (India)
- 78 Utilization, Price and Expenditure Trends for Both Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in the Medicaid Program [121]**
Boyang Bian, Jeff Guo, Chris Kelton, Patricia Wigle. (United States)
- 79 Abstract Withdrawn by Author [122]**
- 80 Antiepileptic Drug Utilization and Medicaid Reimbursement Trends from 1991 to 2008 [123]**
Namita Tundia, Jeff J Guo, Patricia R Wigle, Pamela C Heaton. (United States)
- 81 The Epidemiology, Treatment and Care Patterns, and Medical Resource Utilization Following Hospitalization for Heart Failure [124]**
Caroline Korves, Joshua McHale, Marie-Helene Lafeuille, Rinat Ariely, Mei Sheng Duh. (United States)
- 82 Changes in Insulin Dose in Response to Severe Hypoglycemia in the Diabetes Control and Complication Trial [125]**
Zhiwen Liu, Timothy S Carey, Til Stürmer. (United States)
- 83 Utilization, Price, and Expenditure Trends for Anti-Migraine Drugs in the U.S. Medicaid Program from 1991 through 2008 [126]**
Chien-Hsiang Chiu, Jeff J Guo, Paricia R Wigle, Alex C Lin. (United States)
- 84 Racial and Ethnic Disparities in Quality of Health Care among Adults with Diabetes in the United States in 2005-2006 [127]**
Yan-Jun Zhang, Monica Holiday-Goodman, Aliaksandr Amialchuk, Jing-Bo Wang, Rose Jung. (United States)

- 85 Evaluation of Guideline-Conformity of Initiation of Oral Hypoglycemic Treatment for Incident Diabetes Mellitus Type 2 in Austria [128]**
Wolfgang C Winkelmayr, Margaret R Stedman, Michaela Pogantsch, Peter Wieninger, Anna Bucsics, Alan Brookhart. (United States)
- 86 Knowledge and Attitudes towards Complementary and Alternative Medicine by Pharmacy Students [129]**
Ilse Truter. (South Africa)
- 87 Health Care Resource Utilization among Hispanic and Non-Hispanic White Adults in the United States [130]**
Margaret McDonald, Michael B Lustik. (United States)
- 88 Drug Utilization Study on the Prescribing Indications of Oral Contraceptives in Croatia [131]**
Kristina Bardenheuer, Juergen Dinger, Anita Assmann, Klaas Heinemann, Janko Leddin. (Germany)
- 89 News Reports of Medicines in Relation to Decisions of the Australian Pharmaceutical Benefits Advisory Committee [132]**
Jane Robertson, Marc D Bevan, Emily J Walkom, David A Newby. (Australia)
- 90 Use of Cytochrome P450 Inducers and Inhibitors in Patients with Osteoarthritis Compared to the General Population [133]**
Stephen P Motsko, John Roberts, Dharam Singh, Jill Chappell. (United States)
- 91 Descriptive Analysis of Antipsychotic Prescriptions in Primary Care [134]**
P Prah, I Petersen, I Nazareth, K Walters, D Osborn. (United Kingdom)
- 92 Drug Burden as a Predictor of Adherence to a Newly Prescribed Statin [135]**
Jennifer Polinski, Elisabetta Patorno, Amrita Desai, Wei Liu, Suyog Kamatkar, Kristin Palmsten, Joy Lee, Joshua Gagne. (United States)
- 93 The Challenge of Drug Regimen Surveillance When Changing Level of Care [136]**
Kirsten K Viktil, Hege S Blix, AnneK Eek, TronA Moger, Aasmund Reikvam. (Norway)

Gut

- 94 Validation of ICD-9-CM Codes To Identify Gastrointestinal Perforation (GIP) Cases in Administrative Claims Data in Rheumatoid Arthritis (RA) Patients [137]**
Jeffrey R Curtis, Shih-yin Chen, Winifred Werther, Ani John, David Johnson. (United States)
- 95 Long-Term Statin Use Reduces the Risk of Gallstone Disease – A Population-Based Case-Control Study [138]**
Rune Erichsen, Trine Frøslev, Lars Pedersen, Henrik T Sørensen. (Denmark)
- 96 Trends in the Consumption and Costs of Oral Antidiabetic Drugs in Portugal, 2004-2009 [139]**
Carla Torre, José Guerreiro, Suzete Costa. (Portugal)
- 97 Tysabri TOUCH Prescriber Program Risk Management Program (Risk-MAP) Surveys [140]**
Kelly Hollis, Brian Calingaert, Mark Price, Elizabeth Andrews, Liam Moy, Mariska Kooijmans, Lynda Cristiano, Carmen Bozic. (United States)
- 98 Antibacterial Use and Risk of Acute Pancreatitis: A Case-Control Study Using the National Veterans Affairs Database [141]**
Thamir M Alshammari, Kerry L LaPlante, Brian J Quilliam, Robert Laforge, E Paul Larrat. (United States)
- 99 Potential Diagnostic/Ascertainment Bias Associated with Endoscopic Findings among Bisphosphonates Users [142]**
Robert N Lubwama, Tzuyung D Kou, Julie Chandler. (United States)
- 100 Stable Incidence of Type 1 Diabetes in Children Observed in the Norwegian Prescription Database (NorPD) in the Period 2005-2009 [143]**
Hanne Strøm, Christian Berg, Randi Selmer. (Norway)
- 101 Clinical Outcomes in Familial Adenomatous Polyposis (FAP) Patients with a Long-Term Treatment of Celecoxib: A Matched Cohort Study [144]**
Kui Huang, Lia P Gutierrez, Steffen Bulow, Steven Gallinger, Antoni Castells, Craig J Eagle, James M Church. (United States)

- 102 Temporal Trends in Compliance with the Alosetron Risk Management Program (RMP) [145]**

Kelly Hollis, Pat Tennis, Jean Paul Nicandro, Paul Shin, Carolyn Sweeney, Lee Bennett, Elizabeth Andrews. (United States)

- 103 Influenza and the Incidence of Acute Pancreatitis in a UK Population [146]**

William A Blumentals, Alan Nevitt, Liping Huang, Michael M Peng, M Connie Abelardo. (United States)

Lungs

- 104 Adherence to Inhaled Corticosteroids among Adult Patients Privately Insured [147]**

Marie-Christyne Cyr, Amélie Forget, Lucie Blais. (Canada)

- 105 Characterization of Salmeterol Utilization and Concurrent Asthma Therapy [148]**

Sigal Kaplan, Yulan Ding. (United States)

- 106 Utilization of Cough/Cold Preparations among Pediatrics in Taiwan [149]**

Ching-Lan Cheng, Yea-Huei Kao Yang, Swu-Jane Lin. (Taiwan)

- 107 Risk of Serious Asthma Exacerbations Associated with Long-Acting-Beta-Agonists among Medicaid Patients with Asthma: A Retrospective Cohort Study [150]**

Jeff J Guo, Katherine Tsai, Christine ML Kelton, Boyang Bian, Patricia R Wigle. (United States)

- 108 Evaluating Safety of Long-Acting Beta Agonists (LABAs) in Patients with Asthma [151]**

Boyang Bian, Jeff Guo, Chris Kelton, Patricia Wigle. (United States)

- 109 Drug-Induced ECG Abnormalities in Patients with COPD [152]**

Miriam J Warnier, Marie L de Bruin, Frans H Rutten, Arno W Hoes, Ton de Boer. (Netherlands)

- 110 Economic Evaluation of an Inpatient Medication Reconciliation Process on Medication and Labour Costs [153]**

Fatma Karapinar, Sander D Borgsteede, Jan Zoer, Marjo JA Janssen, Antoine CG Egberts, Patricia MLA van den Bemt, Maurits van Tulder. (Netherlands)

- 111 Off Label Prescribing of Inhaled Corticosteroids to Children with Asthma in Primary Care [154]**

Hajer Elkout, Peter J Helms, Colin R Simpson, James S Mc Lay. (United Kingdom)

Medications in Pregnancy

- 112 Pregnancy Outcomes Associated with Substitution Treatment for Opioid Dependency: A Pilot Study Using Danish Population Registries [155]**

Zhiping Huang, Helen Huang, Anne-Mette Bay Bjørn, Vera Ehrenstein. (United States)

- 113 Treatment of Diabetes before and during Pregnancy [156]**

Anita McGrogan, Julia Snowball, Corinne de Vries. (United Kingdom)

- 114 Increased Risk for Spontaneous Abortion and Preterm Birth Associated with Antidepressant Use in Pregnancy: A Comparison between Continuers and Discontinuers [157]**

Adrienne Einarson, Jacqueline Choi, Pina Bozzo, Gideon Koren, Thomas Einarson. (Canada)

- 115 Fluoxetine and Infantile Hypertrophic Pylorus Stenosis: A Signal from a Birth Defects – Drug Exposure Surveillance Study [158]**

Marian K Bakker, Hermien EK De Walle, Bob Wilffert, Lolkje TW De Jong-van den Berg. (Netherlands)

- 116 Antidepressant Use during Pregnancy and Congenital Malformations: Systematic Review of Study Methods, Confounders and Limitations [159]**

Deborah A Kennedy, Adrienne Einarson, Marcio Machado, Sachi Sakaguchi, Irene Lara, Amy Sharma, Hisaki Fujii, Alexandra Balma-Mena, Hiroaki Aoki, Elena Reydmann, Thomas R Einarson. (Canada)

- 117 Pregnancy Exposure Registries: Prenatal Testing Allowed? [160]**

Susan S Roberts, Jessica D Albano. (United States)

- 118 Trends in Prescriptions for Folic Acid among French Pregnant Women: Assessment of Accordance with Recommendations [161]**

Reginald Riwer, Caroline Hurault, Robert Bourrel, Jean Louis Montastruc, Christine Damase-Michel, Isabelle Lacroix. (France)

- 119 Medication Use during Pregnancy in Out-Patient Setting of an Indian Tertiary Care Hospital [162]**

Gurumurthy Parthasarathi, Nidudi R Veda, Madhan Ramesh, Anand Harugeri. (India)

- 120 Population-Based Antiepileptic Drug Utilization Study in Europe among Pregnant Women [163]**

Janneke Jentink, Christine Damase-Michel, Lolkje TW de Jong-van den Berg. (Netherlands)

- 121 Evaluation of the Representativeness of a Dutch Non-Malformed Control Group with the General Pregnant Population, Are They Useful as Controls for EUROCAT? [164]**
Janneke Jentink, Lolkje TW de Jong-van den Berg. (Netherlands)
- 122 Prevalence of Antidepressant and/or Benzodiazepine Polytherapy during Pregnancy [165]**
Odile Sheehy, Mélanie Soumaille, Martin St-André, Berard Anick. (Canada)
- 123 Socio-Demographic and Lifestyle Predictors of Folic Acid and Multi-vitamin Supplementation in Danish Pregnancy Planners [166]**
Heidi T Cueto, Anders Riis, Lauren A Wise, Elizabeth E Hatch, Kenneth J Rothman, Henrik T Sørensen, Ellen M Mikkelsen. (Denmark)
- 124 Improving Accuracy in Enrollment Targets for Pregnancy Registries [167]**
Deborah Covington, Hadley Mates, Paige Churchill, Amanda Golembesky, Laura McKain. (United States)
- 125 A Combined Comorbidity Score for Predicting 1-Year Mortality in Elderly Patients Using Healthcare Claims Data [168]**
Joshua Gagne, Robert Glynn, Jerry Avorn, Raisa Levin, Sebastian Schneeweiss. (United States)
- 126 National Estimates of Pediatric Inpatient Medication Use in the US in 2008 [169]**
Tamar Lasky, Shirley V Wang, Frank R Ernst, Jay Greenspan, M Liliana Gonzalez. (United States)
- 127 Qualitative Evaluation of Medication Use in Two Different Geriatric Inpatient Populations of a University-Affiliated Hospital [170]**
Jean Frederic Westphal, Cathy Nonnenmacher. (France)
- 128 Assessing the Effectiveness of Counter Matching as a Tool for Improving the Efficiency of the Nested Case Control Design in Pharmacoepidemiological Studies [171]**
Victor A Kiri, Gilbert MacKenzie. (United Kingdom)
- 129 Room for Improvements in Conducting and Reporting Non-Inferiority Randomized Controlled Trials on Drugs [172]**
Grace Wangge, Olaf H Klungel, Kit CB Roes, Anthonius de Boer, Arno W Hoes, Mirjam J Knol. (Netherlands)
- 130 Validation of Claims-Based Diagnostic Codes for Severe Hypoglycemic Events (SHEs) in a Commercially-Insured Population [173]**
Debra F Eisenberg, Gregory W Daniel, Usha Subramanian, Tracy Breen, Rhonda L Bohn, Peter M Wahl, William H Herman. (United States)
- 131 Accuracy of Identifying Outpatient Neutropenia Diagnoses in Claims Data [174]**
Seo Young Kim, Daniel H Solomon, Jun Liu, Gina Chang, Gregory W Daniel, Sebastian Schneeweiss. (United States)
- 132 Extracting Meaningful, Searchable and Discrete Data from Unstructured Medical Text [176]**
Aaron WC Kamauu, Gerasimos Petratos, Anthony Amey, Peter Bechtel, Daniel Dine. (United States)
- 133 Comparison of Two Penalized Regression Methods for Signal Detection [177]**
Marietta Rottenkolber. (Germany)
- 134 A Combined Statistical and Non-Statistical Approach to Assessing Whether Adverse Events Associated with Different Lots of Identical Drug Are Clinically and Statistically Relevant [178]**
Dorian Villegas, Wendy Ye, Fred Schneeweiss, Mark Von Tress, Sam Yonren. (United States)
- 135 The Effect of Reimbursement System Versus Global Financial System on Drug Cost, Percentage of Branded Drug and Adherence of Drug Prescription to Guideline [179]**
Lili Komariah Darmawiredja, Iwan Dwiprahasto, Erna Kristin. (Indonesia)
- 136 Development of an Automated Pharmacovigilance System within the Military Healthcare System [180]**
Trinka Coster, David Fram, Suji Xie, Karl Friedl, Paul Cordts. (United States)
- 137 Between and within Practice Variability among Practices within the Health Improvement Network [181]**
Kevin Haynes, Warren B Bilker, Tom R TenHave, James D Lewis. (United States)
- 138 Signal Detection Biases Caused by the Use of Differentially Reported Non-Serious Events in the FDA AERS Database [182]**
Keith L Altman. (United States)
- 139 A Demonstration of the Importance of Population Specification in Study Design [183]**
Laura E Burleson. (United States)
- 140 Generation of Safety Data in Clinical Trials: What Are Participants' Perspectives of Reporting? [184]**
Elizabeth N Allen, Clare IR Chandler, Sarah G Staedke, Karen I Barnes. (South Africa)
- 141 How To Implement New Statistical Tools in Vaccine Safety? Hurdles Encountered [185]**
Annette Koller Doser, Katharina Hartmann, Griot Monika. (Switzerland)
- 142 Bias Is Worse Than Noise: Handling Missing Data for Confounders in Observational Studies [186]**
Eric P Elkin, Dave P Miller. (United States)
- 143 Development of a Claims-Based Healthcare Safety Sentinel System Featuring Signal Strengthening during Sequential Monitoring [187]**
Peter M Wahl, Sebastian Schneeweiss, Thomas E Wasser, Debra F Eisenberg, Keith Rodgers, Joshua J Gagne, Jeremy A Rassen, Jerry Avorn, Rhonda L Bohn. (United States)
- 144 Automated EMR Data Processing System for Post-Market Surveillance [188]**
Dukyong Yoon, Man Young Park, KiYoung Lee, Rae Woong Park. (Republic of Korea)
- 145 Data-Driven Analysis of Comorbidities Associated with Systemic Lupus Erythematosus in Marketscan Claims Database [189]**
Hans Petri, Debra Maldonato, Noah J Robinson. (United Kingdom)
- 146 Quality of Reporting of Harms in Randomized Controlled Trials: An Example Using Human Papillomavirus (HPV) Vaccines [191]**
Leah M Smith, Jeevitha Srighanthan, Karen KY Poon, Linda E Lévesque. (Canada)
- 147 Evaluating Adherence to Antihypertensive Medication Using Medication Event Monitoring System [192]**
Peter Doro, Ria Benko, Aniko Czako, Maria Matuz, Ferenc Thurzo, Gyongyver Soos. (Hungary)

Methods

- 148 Development of a Comorbidity Score To Predict Disability in Older Adults from Prescription Claims Data [193]**
Marie-France Dubois, Edeltraut Kröger, Nicole Dubuc, Ronald Girard, Réjean Hébert. (Netherlands)
- 149 The Relationship between Bisphosphonate Adherence and Fracture: Is It the Behavior or the Medication? Results from the Placebo Arm of the Fracture Intervention Trial [194]**
Jeffrey R Curtis, Elizabeth Delzell, Lang Chen, Suzanne Judd, Dennis Black, Kristine Ensrud, Lisa Palermo, Monika Safford, Ann Schwartz, Doug Bauer. (United States)
- 150 Linking UK Death Certificate Data to UK Primary Care Data (GPRD) To Obtain Cause of Death [195]**
Efrosini Setakis, Arlene Gallagher, Tim J Williams, Tjeerd P VanStaa. (United Kingdom)
- 151 Nephrogenic Systemic Fibrosis (NSF) and Gadolinium-Based Contrast Agents (GBCAs). A Statistical Simulation Study [196]**
Alexander Michel, Tilo Blenk. (Germany)
- 152 Prediction Equations for Adjusting Reporting Error in Self-Reported BMI [197]**
Lina Titievsky, Andrew G Rundle. (United States)
- 153 Tools and Methods for Sample Size Calculation Using Person-Time Data [198]**
X Zhou, R E Sobel, A Bate. (United States)
- 154 SALOME: A Pilot Study To Test Causality Assessment of Drug-Exposed Acute Liver Failure Cases Using Different Scales [199]**
Ezgi Gulmez, Georges Pageaux, Dominique Larrey, Franco Bissoli, Yves Horsmans, Jacques Bernuau, Bruno Stricker, Douglas Thorburn, Patrick Blin, Nicholas Moore. (France)
- 155 An Algorithm To Identify Practices Common to Both the GPRD and THIN Database [200]**
Bing Cai, Weifeng Xu, Edward Bortnichak, Watson Douglas. (United States)
- 156 Applying Data-Mining Techniques to Paediatric Data within the WHO-UMC Database; the Impact of Vaccines [201]**
S de Bie, KMC Verhamme, SMJM Straus, GW 't Jong, BHC Stricker, MCJM Sturkenboom. (Netherlands)

- 157 Nimesulide Suspension in Acute Upper Respiratory Infection in Asian Indian Paediatric Population: Results from Post Authorization Safety Study [202]**
Manoj Sharma, Arani Chatterjee. (India)
- 158 Educating a Pharmacoepidemiology Researcher on Selecting Optimal Healthcare Databases for Research [203]**
S A Kamani, E L Goehring, Jr, A J Kapasi, B Nguyen-Khoa, V P Singh, J K Jones. (United States)
- 159 Drug Prescription Monitoring System To Estimate Incidence and Prevalence of Type 1 Diabetes [204]**
Marina Maggini, Roberto Da Cas, Carlotta Lunghi, Flavia Pricci. (Italy)
- 160 Missing Data in Primary Care Databases; Problems and a Possible Solution [205]**
Louise Marston, James Carpenter, Kate Walters, Richard Morris, Irwin Nazareth, Irene Petersen. (United Kingdom)
- 161 Sequential Analysis for Safety Surveillance [206]**
Alexander M Walker, Martin Kulldorff. (United States)
- 162 A Real Time Opioid Class REMS: User Acceptance Pilot [175]**
Edgar Adams, Nat Katz, Kevin Flynn, Robin Kinard, Rick Sage. (United States)
- 163 A Real Time Opioid Class REMS: Technical Feasibility [207]**
Edgar Adams, Nat Katz, Kevin Flynn, Robin Kinard, Rick Sage. (United States)
- 164 The RCT Participant Cohort Study [208]**
Daniel O Koralek, Nicolle M Gatto. (United States)
- 165 Evaluation of US Package Inserts Following the Physician Labeling Rule [209]**
James Buchanan, Sally Van Doren. (United States)
- 166 Suitable Study Designs for Pharmacogenetic Research [210]**
F H van der Baan, O H Klungel, D E Grobbee, A CG Egberts, M J Knol. (Netherlands)
- 167 Evaluation of Death Information in Claims Database [211]**
Shuko Nojiri, Tsugumichi Sato, Kiyoshi Kubota. (Japan)

Muscles and Bones

- 168 Persistency and Concurrency Analysis of Leflunomide Therapy [212]**
Sigal Kaplan, Esther Zhou. (United States)
- 169 Effectiveness of Osteoporosis Drugs in Preventing Secondary Fracture in Taiwan [213]**
Tzu-Chieh Lin, Yea-Huei Kao Yang, Chyun-Yu Yang. (Taiwan)
- 170 Nonsteroidal Anti-inflammatory Drug Use and Risk of Venous Thromboembolism: A Population-Based Case-Control Study [214]**
Morten Schmidt, Christian F Christiansen, Erzebét Horvath-Puho, Henrik Toft Sørensen. (Denmark)
- 171 Influence of Socioeconomic Factors on the Persistence of Alendronate Use. A Nationwide Prescription Database Study in Norway [215]**
Helene Devold, Kari Furu, Svetlana Skurtveit, Aage Tverdal, Jan A Falch, Anne Johanne Sogaard. (Norway)
- 172 Effects of Cox-2 Selectivity NSAID Groupings in UGIB and MI ADR Detection Using Bayesian Hierarchical Modeling: EU-ADR Project [216]**
D Prieto, M Molokhia, S Evans, M Schuemie, R Herings, J van der Lei, M Sturkenboom. (United Kingdom)

Pharmacovigilance

- 173 Abstract Withdrawn by Author [217]**
- 174 Incidence Rates of Edema in Solid Tumor Cancer Patients in the THIN Database [218]**
Victor Gastanaga, Chuck Wentworth, Vanitha Ganesh, Gail Hughes, Fei Xue, Mukesh Verma, Isaiah Dimery, Sean Zhao. (United States)
- 175 Pharmacoepidemiological Study of Antiretrovirals in Lagos University Teaching Hospital South West Nigeria [219]**
Ibrahim Adekunle Oreagba, Sikiru Olatunji Usman, Sulaiman Akanmu, Oluranti Opanuga. (Nigeria)
- 176 To Study the Extent of Off-Label Drug Use in Paediatric Population and Occurrence of Fatal ADRs: A 03 Months Study in a Large Multispeciality Hospital in India [220]**
Pradeep Kumar, Arun K Biswas, Pipasha N Biswas. (India)

- 177 To Study the Extent of Off-Label Drug Use in an Adult Population and Occurrence of Fatal ADRs: A 03 Month Study in a Large Multispeciality Hospital in India [221]**
Pradeep Kumar, Arun K Biswas, Pipasha N Biswas. (India)
- 178 Active Monitoring of Antiviral Medications in Korea [222]**
Hye Jin Park, JaYoung Kim, Junghoon Jang, Myung Jung Kim, Young Hoon Kim, Ji-Hye Ha. (Korea)
- 179 Sex-Related Differences in Hospital Admissions Due to Adverse Drug Reactions in the Netherlands [223]**
Eline M Rodenburg, Bruno HCh Stricker, Loes E Visser. (Netherlands)
- 180 Adverse Events with Fatal Outcome, a Ten Year Survey of Iranian Spontaneous Reports Database [224]**
Shadi Yousefian, Gloria Shalviri. (Islamic Republic of Iran)
- 181 Drug Dictionaries Information on the Risk of Stevens-Johnson Syndrome/ Toxic Epidermal Necrolysis: Discrepancies with Pharmacoepidemiology Studies [225]**
Cynthia Haddad, Alexis Sidoroff, Sylvia Kardaun, Maja Mockenhaupt, Daniel Creamer, Jean Claude Roujeau, The RegiS-CAR Study Group. (France)
- 182 Prescription Combination Medicines Significantly Contribute to Acetaminophen Exposure in the U.S. [226]**
Gregory E Powell, Julie I Papay, Ed N Pattishall, Christine M Hunt. (United States)
- 183 Patient Reporting of Adverse Drug Reactions in the UK: Potential Signals Generated by Patients Compared to Healthcare Professionals [227]**
Lorna Hazell, Victoria Cornelius, Saad Shakir, Anthony Avery. (United Kingdom)
- 184 Glaucoma Management in the Patient with Airways Disease: Are We Helping or Harming? [228]**
Andrew L Gilbert, Elizabeth E Roughead. (Australia)

Risk Management / Communication

- 185 Medication Errors Made by Nurses – A Result of Interrelated Human and System Factors [229]**
Monica Bergqvist, Eva Andersén Karlsson, Karin Sparring Björkstén, Carolin Modigh, Lina Benson, Johanna Ulfvarson. (Sweden)
- 186 An Environmental Scan of Risk Minimisation Interventions [230]**
Lenhang Nkeng, Anne-Marie Cloutier, Camille Craig, Jacques Leloir, Yola Moride. (Canada)
- 187 Evaluation of Medication Safety in Neurological Inpatients Using the Clinical Decision Support Software MediQ [231]**
Markus Guzek, Martin Huber, Stefan Russmann. (Switzerland)
- 188 Abstract Withdrawn by Author [232]**
- 189 In-Hospital Therapeutic Risk Management Following a Fall in the Geriatric Population: Taking the Evidence to the Bedside [233]**
Sarah Gabrielle Béland, Antoine Pariente, Marie-Jeanne Kerogat, Judith Latour, Yola Moride. (Canada)
- 190 Characterization of Current Risk Evaluation and Mitigation Strategies (REMS) [234]**
Alicia W Gilsenan, Elizabeth B Andrews, Kelly A Hollis. (United States)
- 191 Regulatory Scientific Advice: Does Company Size Matter? [235]**
Michelle Putzeist, Aukje M Mantel-Teeuwisse, Christine C Gispén-De Wied, Arno W Hoes, Hubert G Leufkens. (Netherlands)
- 192 Characteristics of Patients Prescribed Sitagliptin and Other Oral Antihyperglycemic Agents in a Large U.S. Claims Database [236]**
Bing Cai, Leonid Katz, Charles M Alexander, Deborah Williams-Herman, Cynthia J Girman. (United States)

End Session A

Announcing the
SECOND EDITION

*Registries for Evaluating
Patient Outcomes: A User's Guide*

The Agency for Healthcare Research and Quality (AHRQ) and Outcome are pleased to announce this updated publication, which reflects the work of more than 80 contributors.

.....

The handbook provides guidance on designing, implementing, and evaluating patient registries. Included in the second edition:

- » New methodological developments
- » Emerging topics in registry science, including updates on safety
- » Technological advances
- » 38 case examples from around the world

.....

Request a free copy:

Visit: www.effectivehealthcare.ahrq.gov

Call: 1 (800) 358 9295

Email: ahrqpubs@ahrq.org

Request: AHRQ Publication number 10-EHC049

Glicklich R, Drejer N, eds. *Registries for Evaluating Patient Outcomes, Second Edition*. (Prepared by the Outcome DEcide Center under Contract No. HHS-200-200-500-351.) AHRQ Publication No. 10-EHC049. Rockville, MD: Agency for Healthcare Research and Quality. [In Press].

OUTCOME
DEcide Center

U.S. 1 617 621 1600
Europe +41 (0) 21 321 3560
registries@outcome.com
www.outcome.com

Anti-Infectives

- 1 **Evaluating the Effects of a FDA Boxed Warning on Adverse Event Reporting: Is There a Difference in the Rate of Reporting of Tendon-Related Adverse Events Associated with the Use of Fluoroquinolones after a FDA Boxed Warning?** [316]
Axel Olsen, Mary Mease, John R Hall, Eric Gemmen, William Garvert. (United Kingdom)
- 2 **Adverse Events Induced by Ceftriaxone: A Ten Years Review of Reported Cases to Iranian Pharmacovigilance Centre** [317]
Gloria Shalviri, Shadi Yousefian, Kheirollah Gholami. (Islamic Republic of Iran)
- 3 **The Study of Adverse Drug Reaction of Telbivudine in Chronic Hepatitis B Virus Infection at Siriraj Hospital** [318]
Tramote Tragulpiankit, Naruemon Dhana, Tawesak Tanwandee, Nitiphout Phumjun, Ploylarp Lertvipapath. (Thailand)
- 4 **Comparison of Systemic Antimicrobials (AM) Consumption and Costs in Different Wards of Multi-Profile Hospital** [319]
Ljubov L Kozhuhova, Svetlana A Ratchina, Alexander A FoKin, Elena V Korneva, Vladimir M Mischenko, Roman A Pavlukov. (Russian Federation)
- 5 **Signal Detection Research of Osetamivir Using Administrative Data for Public Insurance** [320]
Suhyun Lee, Chungam Choi, Wan Gyoon Shin. (Korea)
- 6 **Factors Influencing Antimicrobial (AM) Prescribing to Adult Patients with Acute Rhinosinusitis (ARS)** [321]
E Shal, S Ratchina, V Mischenko, L Kozhuhova, S Palyutin, O Reshetko, S Suleymanov, I Toropova. (Russian Federation)
- 7 **A Drug Utilization Study of Posaconazole in French Hospitals** [322]
Helen Huang, Zhiping Huang, Sandrine Coulomb, Antoine Lafuma, Alejandro Arana. (United States)
- 8 **TdP Liability of Fluoroquinolones: Integrated Approach Based on FDA Spontaneous Reports and Literature Data** [323]
Emanuel Raschi, Elisabetta Poluzzi, Ugo Moretti, Fabrizio De Ponti. (Italy)
- 9 **Abstract Withdrawn by Author** [324]

- 10 **Detection of Fluoroquinolone-Induced Tendon Disorders Using a Hospital Database** [325]
Katsuhito Hori, Kasumi Yamakawa, Naoko Yoshida, Kazunori Ohnishi, Junichi Kawakami. (Japan)
- 11 **Trends in Consumption Antimicrobials for Six Years (2003-2008) in Clinical Centre University of Sarajevo** [326]
Begler Begovic, Lejla Begovic, Amra Cabaravdic. (Bosnia and Herzegovina)
- 12 **Exposure to Co-Trimoxazole and the Risk of Cardiac Dysrhythmia** [327]
William A Blumentals, Steven E Elkin, Miriam Adamcova. (United States)
- 13 **Abstract Withdrawn by Author** [328]
- 14 **Concomitant Use of Drugs That Prolong the QT Interval during Methadone Maintenance Treatment** [349]
Klaus Romero, Rowan Frost, Mary Brown, Raymond L Woosley. (United States)

Cardiovascular

- 15 **Antihypertensive Drug Use and Risk of Depression: A Nested Case-Control Study from the Panor@mica Database** [329]
F Salvo, F Bazin, P Noize, A Fourier-Réglat, V Arcoraci, D U Tari, S Moretti, A P Caputi, A Pariente. (France)
- 16 **Interim Results of a Modified Prescription Event Monitoring Study on Ivabradine: Case Series of Utilisation in Patients under the Age of Forty Years** [330]
C Doe, C Fogg, D Layton, Saad AW Shakir. (United Kingdom)
- 17 **Management of Acute Myocardial Infarction in France: Results from the EOLE Cohort** [331]
C Droz, C Dureau, D Thomas, N Danchin, J Tricoire, J Bénichou, F Paillard, P Ducimetière, S Hercberg, H Maïzi, E Guiard, M-A Bernard, P Blin, N Moore. (France)
- 18 **The SOS Project: Stroke Risk and Nonsteroidal Anti-Inflammatory Drugs (NSAIDs). A Systematic Review of Epidemiological Studies** [332]
Cristina Varas-Lorenzo, Brian Calingaert, Nuria Riera-Guardia, Jordi Castellsague, Antoine Pariente, Lorenza Scotti, Miriam CJM Sturkenboom, Susana Perez-Gutthann. (Spain)
- 19 **The SOS Project: Risk of Acute Myocardial Infarction and Use of NSAIDs. A Meta-Analysis of Epidemiological Studies** [333]
Cristina Varas-Lorenzo, Nuria Riera-Guardia, Brian Calingaert, Jordi Castellsague, Francesco Salvo, Federica Nicotra, Miriam CJM Sturkenboom, Susana Perez-Gutthann. (Spain)
- 20 **Effects of Phytosterol/-Stanol-Enriched Margarines on Effectiveness of Statins and Adherence to Therapy** [334]
Simone Eussen, Nynke de Jong, Cathy Rompelberg, Johan Garssen, Monique Verschuren, Olaf Klungel. (Netherlands)
- 21 **Drug Utilization Evaluation on the Combination of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Taiwan** [335]
Wen-Yi Chang, Li-Chia Chen, Li-Jen Cheng. (Taiwan)
- 22 **Past Adherence as a Predictor of Future Adherence to Preventive Drug Treatments** [336]
Colin Dormuth, Amanda Patrick, Sutherland Jenny, Alan Brookhart. (Canada)
- 23 **Identifying the Predictors for Adverse Drug Reaction Due to Angiotensin Converting Enzyme Inhibitors in Indian Hospitalized Patients** [337]
Thiyagu Rajakannan, Laxminarayana K Bairy, Padma GM Rao, Dipesh Patel, Padmakumar Ramachandran. (India)
- 24 **Abstract Withdrawn by Author** [338]
- 25 **Thromboprophylaxis of Patients Receiving Total Knee Replacement: 1998-2002 Versus 2003-2007** [339]
Willemijn M Meijer, Jetty A Overbeek, Kimberly Woodruff, Joseph Jackson, Fernie JA Penning-van Beest, Ron MC Herings. (Netherlands)
- 26 **The Effect of Rosuvastatin on Hemoglobin Levels in Patients with Anemia and Low-Grade Inflammation: A Post Hoc Analysis of the JUPITER Trial** [340]
Maurice A Brookhart, Daniel H Solomon, Robert J Glynn, Paul M Ridker. (United States)
- 27 **Angioedema and ACE Inhibitors or Angiotensin II Receptor Blockers, Revisited** [341]
Rachel L Jones, Genevieve M Gabb. (Australia)

- 28 Statin Use and the Prevalence of Autoantibodies in the Doetinchem Cohort [342]**
HJl de Jong, JW Cohen Tervaert, OH Klungel, PC Souverein, RJ Vandebriel, J Damoiseaux, H van Loveren, WMM Verschuren. (Netherlands)
- 29 Patient's Medication Adherence in Primary Hypertension [343]**
Josip Culig, Marcel Leppee, Jelena Boskovic. (Croatia)
- 30 The Impact of Prescribing Guidelines on Physician Selection of Drug Therapy for Newly Diagnosed Patients with Hypertension in the UK [344]**
Brian Serumaga, Anthony Avery, Rachel Elliott. (United States)
- 31 Association between the Use of Statins and Systemic Lupus Erythematosus [346]**
SRF Saldi, HJl de Jong, PC Souverein, RHB Meyboom, RJ Vandebriel, JW Cohen Tervaert, H van Loveren, OH Klungel. (Netherlands)
- 32 Sibutramine Adverse Drug Reactions [347]**
Pakawadee Sriphiromya. (Thailand)
- 33 Thromboprophylaxis of Patients Receiving Total Hip Replacement: 1998-2002 Versus 2003-2007 [348]**
Willemijn M Meijer, Jetty A Overbeek, Kimberly Woodruff, Joseph Jackson, Fernie JA Penning-van Beest, Ron MC Herings. (Netherlands)

Classical Pharmacoepidemiology

- 34 Signal Detection of Adverse Drug Reactions of Clopidogrel Using Administrative Data for Korean Public Insurance [350]**
Jinhyung Kim, Chungam Choi, Wan Gyoon Shin. (Korea)
- 35 Applied Epidemiology throughout the Lifecycle of Drugs: Two Case Studies [351]**
Quazi Ataher, Anna Greenacre. (United States)
- 36 Drug Use and the Risk of Road Traffic Crashes: Preliminary Results from the French CESIR-U Study [352]**
S Blazejewski, P Philip, R Ribeyreau-Gayon, E Lagarde, PO Girodet, A Pariente, P Noize, JL Montastruc, L Merle, D Orsoni, D Lauque, N Moore. (France)

- 37 Education and Use of Prescribed Drugs [353]**
Aage Tverdal, Solveig Sakshaug, Hege S Blix, Randi Selmer. (Norway)
- 38 The Association of Aggression and Medication Use with Treatment Outcome of Hospitalized Psychiatric Patients [354]**
Laurette E Goedhard, Joost J Stolker, Henk L Nijman, Toine C Egberts, Eibert R Heerdink. (Netherlands)

CNS

- 39 Actual State of Cancer Pain Management [355]**
Hwa J Kim, Joongyub Lee, Moo-song Lee, Byung-joo Park. (Korea)
- 40 The Influence of Using Methylphenidate on the Coming up of Psychiatric Disorders in Children with ADHD [356]**
Churn-Shiouh Gau, Chiou-Fu Chen, Susan Shur-Fen Gau. (Taiwan)
- 41 Trials Assessing Pharmacotherapeutic Management of Aggression in Psychiatric Patients: Comparability with Clinical Practice [357]**
Laurette E Goedhard, Joost J Stolker, Henk L Nijman, Toine C Egberts, Eibert R Heerdink. (Netherlands)
- 42 Complementary and Alternative Medicine for Attention Deficit/Hyperactivity Disorder in the Eastern Cape, South Africa [358]**
Sanmari Snyman, Ilse Truter. (South Africa)
- 43 Validation of a Monte-Carlo Markov Model for Schizophrenia [359]**
Alice Dragomir, Jean-Francois Angers, Jean-Eric Tarride, Ridha Joobier, Sylvie Perreault. (Canada)
- 44 The Association of Early Discontinuation of Antidepressants to Pharmaceutical Market or System Policies [360]**
Anna B Almarsdóttir, Ingunn Björnsdóttir, Atli Sigurjónsson. (Iceland)
- 45 Abstract Withdrawn by Author [361]**
- 46 Risk of Overuse When Taking Benzodiazepines [649]**
Tom J Lindquist, Ivar A Aursnes, Trine Bjørner, Ingunn F Tveté. (Norway)

Drug Utilization Research/ Health Services Research

- 47 Phelophepa Health Care Train: An Epidemiological Overview of the Western Cape in 2009 [362]**
Ilse Truter. (South Africa)
- 48 Factors Associated with Adverse Drug Events in an Intensive Care Unit [363]**
Adriano Max M Reis, Silvia Helena De B Cassiani. (Brazil)
- 49 Effect of the Universal Health Care Scheme on Prescribing Patterns across Thailand [364]**
Saksit Sripa, Christine Bond, Corri Black. (United Kingdom)
- 50 UK/USA Differences in Marketing Claim [365]**
Stephen R Chapman, Nicholas Thayer, Bernard Naughton. (United Kingdom)
- 51 The Use of Antimicrobial Drugs in the Treatment of Diabetic Patients: Analysis of 'Real World Data' from Electronic Health Records [366]**
Svetlana Sergeeva, Darya Dolotova, Nikolay Matveev, Gagik Galstyan. (Russian Federation)
- 52 Prevalence of Adverse Drug Effects/Adverse Drug Reactions in the 200 Most Commonly Prescribed Medications in the United States Corrected for Prescription Volume [367]**
Mary Kiersma, Aleda Hess, Kristin Villa, Brian Shepler, Matthew Murawski. (United States)
- 53 Characteristics and LDL-C Therapeutic Objectives of Patients Receiving Unusual Lipid-Modifying Therapy Regimens [368]**
Gaelle Desamericq, Laurent Laforest, Marie-Sophie Schwalm, Alison Bourke, Melanie Broquet, Eric Van Ganse, Philippe Moulin. (France)
- 54 Drug Utilization Physician Survey of Intron A® in Europe [369]**
Jamie T Laudati, Shirin Ahmed, Eu Jung Jo, Alejandro Arana. (United States)
- 55 Access to Drugs Via the Judiciary Power in Brazil: Obstacles for the Rational Use of Medicines [370]**
Marina Machado, Francisco Acurcio, Cristina Brandão, Daniel Faleiros, Augusto Guerra Jr, Mariângela Cherchiglia, Eli Iola Andrade. (Brazil)

- 56 Socioeconomic Inequalities in Prescription Medicines Use [371]**
Claudia Furtado, João Pereira. (Portugal)
- 57 Abstract Withdrawn by Author [372]**
- 58 Services for Which Pharmacists May Levy a Fee: Primary Care Drug Therapy (PCDT) [373]**
Ilse Truter, Research and Development Task Team South African Pharmacy Council. (South Africa)
- 59 Effects of an Educational Intervention on the Prescribing of Antimalarials in a Nigerian Teaching Hospital [374]**
Obeh Akoria, Peter Akhideno, Stephen Ayinbuomwan, Abimbola Olowofela, Aghogho Akpojevwe. (Nigeria)
- 60 Utilization and Expenditures Trends of Potentiated Penicillins J01 in the Czech Republic in 1997-2008 [375]**
Vladimíra Vojtová, Karel Urbánek, Dominika Hajdú, Petra Langerová. (Czech Republic)
- 61 Drug Consumption in Old-Elderlies Admitted to Hospital between 1994 and 2004 [376]**
ML Laroche, T Penault, S Crépin, JP Charmes, L Merle. (France)
- 62 Determinants of Compliance with Oral Hypoglycemic Agent in Korean Type 2 Diabetic Patients [377]**
Young Sik Kim, Kyoung-Mi Park, Sung Sun-woo, Yun Jun Yang, Young Sung Suh. (Korea)
- 63 Prescribing in Compliance with Patient Formularies Increases Primary Adherence in Patients Receiving Electronic Prescriptions [378]**
Michael A Fischer, Niteesh K Choudhry, Jerry Avorn, Sebastian Schneeweiss, William H Shrank. (United States)
- 64 Comparison of Prescribing Patterns for Asthma in Five European Countries [379]**
Laurent Laforest, Marie-Sophie Schwalm, Marion Dufour, Mélanie Broquet, Alison Bourke, Eric Van Ganse. (France)
- 65 Could Adverse Reactions of Antibiotic Drugs in Children Be Detected in a Prescription Database? [380]**
Josta de Jong, Jens HJ Bos, Tjalling W de Vries, Lolkje TW de Jong - van den Berg. (Netherlands)
- 66 Drug Utilization Patterns of Antiplatelet Therapies among the Older Adults in Taiwan [381]**
Hsiang-Wen Lin, I-Wen Yu. (Taiwan)
- 67 Correlates of Intentional Interruption of Inhaled Corticosteroids and Spontaneous Changes in Doses by Asthma Patients: Results from a Pharmacy-Based Study [382]**
Laurent Laforest, Eric Van Ganse, Mélanie Broquet, Cécile Ritleng, Gilles Devouassoux, Geneviève Chamba, French Council of Pharmacists. (France)
- 68 Long-Term Trends in Immunosuppressants Utilization the Czech Republic [383]**
Karel Urbanek, Jan Strojil, Vladimira Vojtova, Petra Langerova. (Czech Republic)

Gut

- 69 Uncontrolled Type 2 Diabetes Treated with Oral Hypoglycaemic Agents (OHA) in Monotherapy: Therapeutic Behaviour in Primary Care in France [384]**
B Balkau, S Halimi, JF Blicke, E Tocque, E Amelineau, S Bouée. (France)
- 70 Hepatic Risk among Patients with Chronic Pain: A Retrospective Cohort Study [385]**
Yingkai Cheng, Dale Marmaduke, Antonio Crucitti, Sharon Hoog, Indiana Strombom. (United States)
- 71 Antivertigo and Antiemetic Prescribing to Children and Adolescents [386]**
Ilse Truter. (South Africa)
- 72 Factors Associated with the Initiation of Proton Pump Inhibitors in New Corticosteroid Users [387]**
Jeffrey C Munson, Peter M Wahl, Gregory Daniel, Stephen E Kimmel, Sean Hennessy. (United States)
- 73 Treatment of Rare Diseases in Brazil [388]**
Cristina Mariano Ruas Brandao, Marina Amaral Ávila Machado, Anderson Lourenço da Silva, Francisco de Assis Acurcio. (Brazil)
- 74 Final Results from a Retrospective Cohort Study of the Incidence of Acute Pancreatitis in Exenatide Initiators Compared to Other Antidiabetic Drug Initiators [389]**
David D Dore, Gary L Bloomgren, Made Wenten, Rebecca A Noel, Daniel K Braun, John D Seeger. (United States)
- 75 Use of Serotonergic Drugs and the Risk of Bleeding [390]**
Bertha Maria Verdel, Patrick C Souverein, Eibert R Heerdink, Hubert GM Leufkens, Toine CG Egberts. (Netherlands)
- 76 Antidiabetic Utilization and Prescribing Patterns in Outpatients of Diabetic Pay-for-Performance Program [391]**
Ju-Huei Tseng, Li-Chia Chen. (Taiwan)
- 77 Pulmonary and Cardiovascular Safety of Inhaled Insulin in a Real-World Setting: The Exubera Large Simple Trial (VOLUME) [392]**
Nicolle M Gatto, Francesca M Kolitsopoulos, Richard J Riese, William T Duggan, Neville C Jackson. (United States)
- 78 Long-Term Patterns of Statin Therapy in Patients with Type 2 Diabetes Mellitus Compared to Long-Term Oral Antidiabetic Medication Patterns [393]**
Egbert Lamberts, Giel Nijpels, Jacqueline Dekker, Laura Welschen, Marcel Bouvy, Patrick Souverein, Jacqueline Hugtenburg. (Netherlands)
- 79 Abstract Withdrawn by Author [394]**
- 80 DPP-4 Inhibitors and the Occurrence of Infections: A Nested Case-Control Study [395]**
Marjolein J Willemsen, Aukje K Mantel-Teeuwisse, Sabine M Straus, Toine C Egberts, Hubert G Leufkens. (Netherlands)
- 81 Factors Associated with Short-Term Adherence to Dietary and Lifestyle Guidelines in Secondary Prevention of Acute Myocardial Infarction in Real Life Practice in France (EOLE Cohort) [396]**
S Herberg, D Thomas, C Droz, C Dureau, P Ducimetière, F Paillard, J Tricoire, M-A Bernard, J Bénichou, N Danchin, L Guize, P Blin, N Moore. (France)
- 82 Japan Statin Study (JSS), a Prospective Case-Cohort Study for Monitoring Multiple Adverse Events: Rationale, Design and Characteristics of Study Subjects [397]**
Shigeru Kageyama, Masaki Kitamura, Akira Kokan, Kiyoshi Kubota, Kenichi Matsui, Nobuhiro Ooba, Takao Orii, Tsugumichi Sato, Yoshihiro Shimodozono, Hiromi Uehara, Mitsunori Yagame, Yukari Yaju, Takuhiro Yamaguchi. (Japan)
- 83 Is There an Association between Selective Serotonin Reuptake Inhibitor Use and Uncomplicated Peptic Ulcers? – A Population-Based Case-Control Study [398]**
Michael Dall, Ove B Schaffalitzky de Muckadell, Annmarie Touborg Lassen, Jesper Hallas. (Denmark)

84 Does the Omega-3 Prescription Change the Post-MI Lifestyle Adjustment? Results from the EOLE Cohort [399]

C Dureau, C Droz, D Thomas, N Danchin, J Tricoire, J Bénichou, F Paillard, P Ducimetière, S Hercberg, H Maïzi, E Guiard, M-A Bernard, P Blin, N Moore. (France)

Methods

85 Challenges of Measuring Medicine Compliance: The Australian Context [400]

Louise Bartlett, Maxine Robinson. (Australia)

86 Abstract Withdrawn by Author [401]

87 Research Working Groups on Drug Utilization across Europe [402]

L Ibáñez, H Petri, P Solari, E Ballarín, M Sabaté, J Hasford, S Yeboa, K L Goh, JR Laporte, J Fortuny, R Schlienger. (Spain)

88 Use of NSAIDs in France: Analysis from Reimbursement (CNAM-TS) Database [403]

Manoj Sharma, Ezgi Gulmez, Regis Lassalle, Nicholas Moore. (India)

89 How Can the Economic Impact of Drug-Related Morbidity Be Measured? A Systematic Literature Review [404]

Hanna Gyllensten, Anna K Jönsson, Clas Rehnberg, Anders Carlsten. (Sweden)

90 A Tool for Facilitating Comparability in Prospective Observational Studies [405]

Victor A Kiri, Martin Lang, Gary Coward. (United Kingdom)

91 Drug Safety Data Mining with a Tree-Based Scan Statistic [406]

Martin Kulldorff, Inna Dashevsky, Taliser Avery, Arnold K Chan, Robert L Davis, David Graham, Susan E Andrade, Denise Boudreau, Margaret J Gunter, Lisa Herrinton, Pam Pawloski, Marsha A Raebel, Douglas Roblin, Richard Platt, Jeffrey S Brown. (United States)

92 Development of Hospital Based Computerized Drug Safety Database [407]

Thiyagu Rajakannan, SurulivelRajan Malayasamy, Rajesh Vilakkthala, Padma GM Rao, Laxminarayana K Bairy. (India)

93 Joinpoint Regression To Examine the Impact of Drug Safety Warnings on Drug Utilization Trends When Interrupted Time-Series Analysis Is Not Feasible [408]

CY Chen, Almut Winterstein. (United States)

94 Is There a Need for Better Communication of Benefit Risk of Medicines to Patients and Prescribers? [409]

Deborah Szafir, Philip Watson, Simon Ingate, Francois Lucas, Swapu Banerjee, Philippe Van der Auwera. (United Kingdom)

95 Developing an Indicator-Based Performance Tool for Pharmacovigilance Systems [410]

Jude I Nwokike, Mohan P Joshi, Andy Stergachis, Shabir Banoo. (United States)

Muscles and Bones

96 Characteristics of Exposure to Non-Steroid Anti-Inflammatory Drugs in European Databases [411]

Frank de Vries, Helle Kieler, Liset van Dijk, Tobias Svensson, Tjeerd van Staa. (United Kingdom)

97 Assessing the Risk of Osteonecrosis of the Jaws (ONJ) Due to Bisphosphonates Therapy: A Nested Case-Control Study [412]

Francesco Lapi, Achille Caputi, Giovanni Corrao, Nicola Montanaro, Miriam Sturkenboom, Dario Gregori, Flavia Carle, Angelo Menna, Annarita Vestri, Giampiero Mazzaglia. (Italy)

98 Analysis of Strontium Ranelate Utilisation from Prescription-Event Monitoring (PEM): Focus on 'Off Label' and Special Populations Use in Support of Risk Management [413]

Vicki Osborne, Deborah Layton, Saad AW Shakir. (United Kingdom)

99 Prescribing of Fall-Risk Increasing and Fracture-Preventing Drugs in Older Hip Fracture Patients: Observational Study [414]

Christina Sjöberg, Lina Bladh, Lars Klintberg, Dan Mellström, Claes Ohlsson, Susanna M Wallerstedt. (Sweden)

100 Analysis of Patient Exposure for Enbrel Using Insurance Claims Database [415]

Fei Xue, Jason Yuan, Victor Gastanaga, Scott Stryker, Gail Hughes, Peter McCroskery, Sean Zhao. (United States)

101 Maternal Use of Codeine and Other Analgesics in Sweden [416]

Anders Sundström, Fredrik Granath, Tobias Svensson, Helle Kieler. (Sweden)

Other

102 Administrative Complexities for a European Observational Study [417]

Ezgi Gulmez, Séverine Lignot, Corinne de Vries, Miriam Sturkenboom, Patrick Blin, Nicholas Moore. (France)

103 The Mondriaan Project: The Dutch Healthcare Landscape as a Population Laboratory [418]

Olaf H Klungel, Marc C Rietveld, Mark CH de Groot, Ronald P Stolk, Maarten J Postma, Hubert GM Leufkens, Toine CG Egberts, Anke M Hovels, Lex van de Langerijt, Willem de Bruijn, Arno W Hoes, Diederik E Grobbee. (Netherlands)

104 Adherence to Medication Safety Practices Recommendations in Developing Countries: Data from Saudi Arabia [419]

Hisham Aljadhey, Abdulaziz Alhusan, Khaled Alburaihan, Mansour Adam, Mohammed Al-sultan, Michael Murray, David Bates. (Saudi Arabia)

105 Assessment of the Representativity of In-Patient Hospital Diagnoses in the German Pharmacoepidemiological Research Database [420]

Tania Schink, Edeltraut Garbe. (Germany)

106 The Relative Value of EMRs and Claims Data in Health Services Research [421]

S L West, W G Johnson. (United States)

Pharmacovigilance

107 Multiple Drug Exposure and Severity of Adverse Drug Reactions [422]

Francisco Batel-Marques, Nuno Craveiro, Ana Filipa-Macedo, Carlos Fontes-Ribeiro, Margarida Caramona, Tice Macedo. (Portugal)

108 Utilization of Medical Information Databases in Drug Safety Evaluation Process in PMDA [423]

Ayumi Endo, Chieko Ishiguro, Eiko Tada, Maki Noguchi, Kazuhiro Matsui. (Japan)

109 Lifestyle Drugs and Psychiatric Adverse Events in Randomised Clinical Trials [424]

M J Willemen, A K Mantel-Teeuwisse, S M Straus, A C Egberts, H G Leufkens. (Netherlands)

POSTER SESSION B Saturday, August 21

110 The Views of Reporters to the UK Yellow Card Scheme on the Importance of Direct Patient Reporting [425]

Janet Kraska, Julia Taylor, Anthony J Avery. (United Kingdom)

111 Evaluation of Anaphylaxis Patients Using Commercially Available Japanese Claim Data [426]

Ayumi Endo, Chieko Ishiguro, Maki Noguchi, Eiko Tada, Kazuhiro Matsui. (Japan)

112 Preventability of Reported Adverse Drug Reactions to the Swedish Medical Products Agency [427]

Anna K Jönsson, Henrik Lövborg, Ingela Jacobsson, Thomas Bradley, Staffan Hägg. (Sweden)

113 Monitoring the FDA AERS Database To Identify Safety Issues: Does the Need Diminish as Product Time on the Market Increases? [428]

John Watson, Stephanie Reisinger, Jonathan Morris. (United States)

114 A Novel Approach To Review of Batch Related Adverse Event Reports [429]

Steven R Bailey, Peter Huber, Robert Maroko, Robert Azadian. (United States)

115 Abstract Withdrawn by Author [430]

116 An Evaluation of the Impact of REMS on Spontaneous Reporting for Marketed Products [431]

Reema Jain. (United States)

117 A Statistical Analysis Approach to Trend Analysis within a Company Safety Database [432]

Steven R Bailey, Peter Huber, Robert Azadian, Frank D'Angelo, Robert Maroko. (United States)

118 Documentation Grading To Assess Systematic Variability in the Quality of Individual Case Safety Reports [433]

Tomas Bergvall, Jessica Nilsson, Richard Hill, G Niklas Norén, Marie Lindquist. (Sweden)

119 Comparison of Quantitative Signal Detection Using Observational and Spontaneous Adverse Event Data [434]

Gregory E Powell, Patrick B Ryan, Edward N Pattishall. (United States)

120 Abstract Withdrawn by Author [435]

Poster Walk Biologics SIG

121 Critical Issues in Comparing the Use of Biologicals across Various European Countries: TNF Inhibitors as Case Study [436]

J M Hoeberl, A K Mantel-Teeuwisse, L van Dijk, R O Laing, H GM Leufkens. (Netherlands)

122 Treatment Patterns in a Large U.S. Medical-Claims Based Cohort of Breast Cancer (BC) Patients Receiving HER2 Directed Therapy [437]

Lisa Wang, Laura Chu, Sam Agresta, Wei Dong. (United States)



Meet with i3 Drug Safety experts at our booth.

- Drug Safety & Epidemiology
 - Clinical Research
 - Strategic Regulatory Services
 - Data Services
 - Drug Safety & Epidemiology
 - Late Phase Research
 - Health Economics & Outcomes Research
 - Pharma Informatics
 - Staffing & Outsourcing
- Cardiology
- Central Nervous System
- Oncology
- Respiratory & Infectious Disease
- Endocrinology & Metabolic Disease

Our partnership. Their peace of mind.

i3 Drug Safety provides comprehensive pharmacoepidemiology and pharmacovigilance services. Rooted in scientific rigor, using innovative methods and proven expertise, i3 Drug Safety can customize its services for work of any scope or speciality, from safety surveillance and risk assessment in clinical development to post-approval pharmacovigilance. www.i3global.com

i3
The company of specialists.

- 123 Predictors of Tuberculosis Testing in Prescribers of Anti-Tumor Necrosis Factor (TNF) Agents in the European Union [438]**
Meredith Y Smith, Brian Attg, Thomas Eagle. (United States)
- 124 Acute Pancreatitis after Quadrivalent Human Papillomavirus Vaccination: Reports to a Post-Marketing Passive Surveillance System, 2006 – 2009 [439]**
Amy Steffey, Rhonda Lizewski, Andrea Sutherland, Jeff Roberts, Nancy Miller, Robert P Wise. (United States)
- 125 Effectiveness of Recruiting and Retention Strategies for Clinical Studies of Drugs, Medical Devices, and Biologics [440]**
Ellen Pinnow, Mary E Ritchey, Andrea Tilley, Danica Marinac-Dabic. (United States)
- 126 Acute Hemolysis Consistent with Intravascular Hemolysis in Patients Receiving WinRho To Treat ITP [441]**
Aileen Buckler, Nisha Jain, Basil Golding, Faith Barash, Robert Wise. (United States)
- 127 Trastuzumab (T) Treatment Outcomes According to Concomitant Chemotherapy Regimen: Overall Survival (OS) of HER2+ Metastatic Breast Cancer (MBC) Patients [442]**
Sallie-Anne Pearson, Preeyaporn Srasuebkul, Carole Harris, Robyn Ward, Timothy Dobbins. (Australia)
- 128 Updated Post-Licensure Safety Surveillance for Recombinant Human Coagulation Factor VIIa [443]**
Alan C Ou, Nisha Jain, Charles W Maplethorpe, Robert P Wise. (United States)
- 129 The Use of Observed vs Expected Analyses in Real-Time Vaccine Safety Surveillance in the UK during the H1N1 Pandemic [444]**
Suzie Seabroke, Philip Bryan, Lesley Wise. (United Kingdom)
- 130 Risk of Cardiovascular Events among 3,865 Elderly Diffuse Large B-Cell Lymphoma Patients Treated with Doxorubicin-Based Chemotherapy +/- Rituximab: A Population-Based Study [445]**
Huei-Ting Tsai, Ruth Pfeiffer, C Ola Landgren. (United States)
- 131 Proactive Pharmacovigilance of the Human Papillomavirus (HPV) Vaccine [446]**
Jenny Wong, Suzie Seabroke, Saira Mahmood, Philip Bryan. (United Kingdom)

Poster Walk Comparative Effectiveness Research SIG

- 132 Comparative Safety of Antipsychotic Medications in Ederly Medicaid-Eligible Nursing Home Patients [447]**
Sebastian Schneeweiss, Krista Huybrechts, Tobias Gerhard, Mark Olsson, Jeremy A Rassen, Raisa Levin, Judith Lucas, Stephen Crystal. (United States)
- 133 Population-Based Study: Adherence Impact of Antihypertensive Agents on Vascular Events among Patients with Ischemic Stroke [449]**
Sylvie Perreault, Robert Cote, Alice Dragomir. (Canada)
- 134 Prioritizing Comparative Effectiveness Research [450]**
A M Walker, A R Patrick, M S Lauer, C T Laurencin, M G Marin, R Platt, P Stang, S Schneeweiss. (United States)
- 135 Tiotropium and Severe COPD Exacerbations – Comparisons with Long-Acting 2-Mimetics [451]**
Ana Afonso, Katia MC Verhamme, Charlotte van Noord, Mendel Haag, Guy GO Brusselle, Miriam CJM Sturkenboom. (Netherlands)
- 136 Delayed Progression to Insulin in Patients with Type 2 Diabetes Mellitus Treated with Thiazolidinediones: A Population-Based Cohort Study [452]**
Colin R Dormuth, Greg Carney, Jenny Sutherland. (Canada)
- 137 Current and Potential Uses of Clinical Registries for Comparative Effectiveness Research [453]**
Richard Gliklich, Michelle B Leavy, Christina D Mack, Laura Whiteside, Dan Champion, Barbara Bartman. (United States)
- 138 Abstract Withdrawn by Author [454]**
- 139 Examination of Effects of Regression to the Mean and Medication Adherence on HbA1C Levels among New Users of Oral Antidiabetic Drugs [455]**
Carlos Grijalva, Robert Greevy, Mary Huizinga, Christianne Roumie, Harvey Murff, Shirley Liu, Adriana Hung, Marie Griffin. (United States)
- 140 The Standard Care Versus Celecoxib Outcome Trial (SCOT): A Large Streamlined Safety Study [457]**
Isla S Mackenzie, Daniel Rutherford, Evelyn A Findlay, Chris J Hawkey, Ian Ford, Thomas M MacDonald. (United Kingdom)

- 141 Effectiveness of Zanamivir (RELENZA) Prophylaxis for Influenza [458]**
Kandace Amend, Vani Vannappagari, Maria Wood-Armay, Rob Gately, John D Seeger. (United States)

Poster Walk Database SIG

- 142 Chronic Heart Failure Treated with Loop-Diuretics Is Associated with Increased Risk of Hospitalization with Pneumonia: A Population-Based Case-Control Study [459]**
Sinna P Ulrichsen, Reimar W Thomsen. (Denmark)
- 143 Validation of Psoriasis and Its Prevalence, Treatment, and Severity in the Health Improvement Network (THIN) [460]**
N M Seminara, K Abuabara, D B Shin, S E Kimmel, D Margolis, A Troxel, J M Gelfand. (United States)
- 144 Linking Primary Care Data (UK GPRD) to Hospital Records (HES) [461]**
Susan C Eaton, Efrosini Setakis, Tim Williams, Tjeerd Van Staa. (United Kingdom)
- 145 Abstract Withdrawn by Author [462]**
- 146 Validation of a Claims-Based Diagnostic Code for Stevens-Johnson Syndrome (SJS) in a Commercially-Insured Population [463]**
Gregory W Daniel, Debra F Eisenberg, Judith K Jones, Earl L Goehring, Peter Winters, Jay Levin, Peter M Wahl, Rhonda L Bohn. (United States)
- 147 Lipid Levels among Antiretroviral (ARV) Naïve HIV-Infected Individuals in Routine Care [465]**
H M Crane, J AC Delaney, E Brown, J W Willig, M Mugavero, P W Hunt, B Rodriguez, W C Matthews, M Saag, M M Kitahata. (United States)
- 148 The Incidence of Pancreatic and Thyroid Cancers in Patients with Type 2 Diabetes Mellitus Compared to Nondiabetics in a Managed Care Population [466]**
Kwame Appenteng, Rebecca Noel, Dale Marmaduke, John Roberts, Stephen Motsko. (United States)
- 149 Exposure Classification for Case-Control Studies When Variables Are Both Confounders and Intermediaries [468]**
Andrea Gruneir, Connie Marras, Hadas Fischer, Xuesong Wang, Sudeep Gill, Paula Rochon, Geoffrey Anderson. (Canada)

Poster Walk Drug Utilization SIG

- 150 Primary Care Prescribing of Anti-Osteoporotic Type Medications Following Hospitalisation for Fractures [469]**
Bernie McGowan, Miriam C Casey, Joe Marry, Kathleen Bennett. (Ireland)
- 151 Adherence to Osteoporosis Drugs and Fracture Prevention: No Evidence of Healthy Adherer Bias in a Frail Cohort of Seniors [470]**
Suzanne M Cadarette, Daniel H Solomon, Jeffrey N Katz, Amanda R Patrick, M Alan Brookhart. (Canada)
- 152 Utilisation of Non-Steroidal Anti-Inflammatory Drugs in Quebec, Canada: Is There a Change in the Patient Risk Profile after the Withdrawal of Rofecoxib? [471]**
Elham Rahme, Jean-Philip Lafrance, Jean-Pascal Roussy, Suzanne Morin. (Canada)
- 153 Clopidogrel Use and Mortality after Peptic Ulcer Bleeding: A Population-Based Cohort Study [472]**
Morten Schmidt, Anders Riis, Christian F Christiansen, Timothy L Lash, Henrik Toft Sørensen. (Denmark)
- 154 Persistence and Compliance of Deferoxamine (DFO) Versus Deferasirox (DFX) in Medicaid Patients with Sickle-Cell Disease (SCD) [473]**
L B Jordan, F Vekeman, A Sengupta, M Corral, A Guo, M S Duh. (United States)
- 155 Why Do Hospital Patients Experience Adverse Drug Events? [474]**
A Dequito, P Mol, J van Doormaal, R Zaal, P van den Bemt, F Haaijer-Ruskamp, J Kosterink. (Netherlands)
- 156 Effectiveness of Cardioprotective Drugs in Elderly Individuals with Type 2 Diabetes [475]**
Caroline Sirois, Jocelyne Moisan, Jean-Pierre Grégoire. (Canada)
- 157 Trends in Use of Gastroprotective Strategies with NSAID Treatment in the United Kingdom, Italy, and the Netherlands [476]**
V Valkhoff, E van Soest, J Dieleman, R Schade, G Mazzaglia, M Molokhia, E Kuipers, M Sturkenboom. (Netherlands)

158 Timing of Prophylaxis Relative to Respiratory Syncytial Virus Seasons [477]

Christian Hampp, Almut G Winterstein. (United States)

159 For What Diagnoses Are Psychotropic Medications Being Prescribed? Implications for Understanding Off-Label Prescribing [478]

Tami L Mark. (United States)

Poster Walk Molecular Epidemiology SIG

160 Association between HTR2C Gene Polymorphisms and the Metabolic Syndrome in Patients Using Antipsychotics: A Replication Study [479]

Arne Risselada, Jelle Vehof, Richard Brugge-geman, Bob Wilffert, Dan Cohen, Asmar Al Hadithy, Johan Arends, Hans Mulder. (Netherlands)

161 Association between the ADRA2A 1291 C/G Polymorphism and the Metabolic Syndrome [480]

Arne Risselada, Jelle Vehof, Richard Brugge-geman, Bob Wilffert, Dan Cohen, Asmar F Al Hadithy, Johan Arends, Hans Mulder. (Netherlands)

162 Dosing Algorithm for Phenprocoumon; Using Patient Characteristics and Genotype Information To Calculate the Optimal Monitoring Dose [481]

Rianne MF van Schie, Saskia le Cessie, Frits R Rosendaal, Anke-Hilse Maitland-van der Zee, The EU-PACT Study Group. (Netherlands)

163 Validation of Warfarin Pharmacogenetic Algorithms in Real Clinical Practice [482]

Melina Marin-Leblanc, Sylvie Perreault, Marie-Pierre Dubé. (Canada)

164 Prognostic Value of Chronic Kidney Disease in Patients with Coronary Heart Disease: Role of GFR Estimating Equations [483]

Qiu-Li Zhang, Hermann Brenner, Wolfgang Koenig, Dietrich Rothenbacher. (Germany)

165 Candidate Genes Associated with Phenprocoumon Maintenance Dosage [484]

Martina Teichert, Mark Eijgelsheim, Loes E Visser, Bruno HC Stricker. (Netherlands)

166 Early-Adulthood Obesity [EOb] Modifies the Cisplatin [C]-DNA Repair Gene Polymorphism XPD ASP312ASN [X] Relationship in Esophageal Cancer (EC) Survival: A Combined Pharmacogenetic-Molecular Epidemiologic Analysis [485]

Daniel Renouf, Linda Coate, Rihong Zhai, Matthew Kulke, Rebecca S Heist, Penelope Bradbury, Wei Xu, Zhengfei Chen, Kofi Asomaning, John Wain, Li Su, Geoffrey Liu, David C Christiani. (Canada)

167 Change in Drug Utilization Patterns in Statin Users with Increased Creatine Phosphokinase (CPK) Levels [486]

Frank de Vries, Efosini Setakis, Tjeerd van Staa. (United Kingdom)

168 Prognostic Role of Genetic Polymorphisms in Head and Neck Cancer (HNC) Survival [487]

Abul K Azad, Geoffrey Liu, Wei Xu, Dangxiao Cheng, Elodie Samson, Maryam Mirshams, Zhuo Chen, Sevta Savas, John Waldron, Isabelle Bairati, Meyer Francois. (Canada)

169 The Effect of Daily Aspirin on Ovarian Cancer Serum Biomarkers in Healthy Postmenopausal Women [488]

Kimberly Lowe, Robin Forest, Jason Thorp, Lindsay Bergan, CY Wang, Anne McTiernan, Nicole Urban. (United States)

170 Genetic Polymorphisms as Prognostic/Predictive Biomarkers of Single-Agent Erlotinib Therapy in NCIC-CTG BR.21 Non-Small Cell Lung Cancer (NSCLC) Trial [489]

Geoffrey Liu, Dangxiao Cheng, Aurelie Le Maitre, Ni Liu, Zhuo Chen, Lesley Seymour, Keyue Ding, Frances Shepherd, Ming Tsao. (Canada)

POSTER SESSION B Saturday, August 21

Poster Walk Pregnancy SIG

- 171 The Safety of Citalopram Exposure during Pregnancy – Maternal Characteristics, Birth Outcomes and Early Hospital Admissions for 1157 Children [490]**
Lyn Colvin, Linda Slack-Smith, Fiona J Stanley, Carol Bower. (Australia)
- 172 Exposure to Anti-Infective Drugs during Pregnancy and the Risk of Small-for-Gestational-Age Newborns [491]**
Fabiano Santos, Odile Sheehy, Sylvie Perreault, Ema Ferreira, Anick Bérard. (Canada)
- 173 SSRI Drug Use during Pregnancy and Perinatal Outcome [492]**
Heli Malm, Miia Artama, Mika Gissler, Annukka Ritvanen. (Finland)
- 174 Drug Use during Pregnancy in South-western France [493]**
Anne-Laure Voisin, Philippe Latry, Claude Peter, Karin Martin-Latry. (France, Metropolitan)
- 175 EFEMERIS, the French Prescription Database in Pregnant Women: A 4 Year-Follow Up [494]**
Christine Damase-Michel, Isabelle Lacroix, Caroline Hurault, Sylvie Kessler, Claudine Guitard, Sabine Vidal, Jean Louis Monstruc. (France)
- 176 Oral Antibiotic Prescribing in Pregnancy in United Kingdom [495]**
I Petersen, R Gilbert, A Rudolfi, S Evans, I Nazareth. (United Kingdom)
- 177 Elevated Risk of Preeclampsia in Pregnant Women with Depression: Disease vs. Antidepressants [496]**
Kristin Palmsten, Soko Setoguchi, Andrea V Margulis, Amanda R Patrick, Sonia Hernández-Díaz. (United States)
- 178 SSRI and Risk of Congenital Cardiac Abnormalities [497]**
Irene Petersen, R Gilbert, S Evans, L Marston, I Nazareth. (United Kingdom)
- 179 Pregnancy Loss in Patients with Type 1 or Type 2 Diabetes during Pregnancy [498]**
Anita McGrogan, Julia Snowball, Corinne de Vries. (United Kingdom)
- 180 Birth Outcomes among Women Exposed to Oseltamivir (Tamiflu) During Pregnancy [499]**
Tobias Svensson, Fredrik Granath, Olof Stephansson, Helle Kieler. (Sweden)

End Session B

THE DEGGE GROUP, LTD. Drug Safety Research and Information

Risk Management: Risk Evaluation & Mitigation Strategies, Program Evaluation, Registries;

Pharmacoepidemiology: Natural History of Disease, Phase IV Studies, and Literature Reviews;

Pharmacovigilance: Spontaneous Reports, AERS, and Safety & SOP Audits;

Scientific Advisory Panel / Endpoint Adjudication Management, and CRO Oversight



Visit our Booth to see how we can help you,
or visit: www.deggegroup.com

22 years of Consulting and Research in Drug Safety and Pharmacoepidemiology

Bridging Scientific Expertise with Real World Data



80+ database profiles in 17 countries: Asia (China, India, Korea, Taiwan), Europe (Denmark, France, Germany, Italy, Netherlands, Norway, Spain, Sweden, United Kingdom), New Zealand, Australia, and North America (Canada, USA)

www.bridgetodata.org

Your connection to healthcare databases worldwideSM

1616 N. Fort Myer Drive, Suite 1430, Arlington, VA 22209, USA Tel: +1 703 894-0804 Fax: +1 703 894-0803

Anti-Infectives

- 1 **Exposure to Quinolones during Pregnancy: Lack of Association with an Increased Risk for Birth Defects and Other Adverse Pregnancy Outcomes [578]**
Ilan Matok, Gideon Koren, Rafael Gorodischer, Amalia Levy. (Canada)
- 2 **Systemic Antibiotic Use among Children in Germany. An Analysis of Outpatient Dispensations Based on Claims Data of German Statutory Health Insurances [579]**
Jakob Holstiege, Edeltraut Garbe. (Germany)
- 3 **Adverse Events Associated with Antibiotic Use [580]**
Sharon B Meropol, A Russell Localio, Joshua P Metlay. (United States)
- 4 **Evaluation of Antibiotic Prescribing for Acute Upper Respiratory Tract Infection in Private Hospital in Indonesia [581]**
Purwati Pole Rio, Iwan Dwiprahasto, Jarir AT Thobari. (Indonesia)
- 5 **Risk Factors for Non-Tuberculous Mycobacterial Infections Post-Transplantation [582]**
Christopher Vinnard, Sarah Longworth, Ingi Lee, Marie Synnestvedt, Sims Karen, Blumberg Emily. (United States)
- 6 **Vancomycin Use in Children Hospitalized in the United States in 2008 [583]**
Tamar Lasky, Jay V Greenspan, Frank R Ernst, Shirley V Wang, M Liliana Gonzalez. (United States)
- 7 **The Rate of Adherence to an Antibiotic Treatment Guideline [584]**
Maria Matuz, Ria Benko, Edit Hajdu, Peter Doro, Gyongyver Soos. (Hungary)

Burden of Disease/ Epidemiology of Illness

- 8 **Prevalence of Erythema Multiforme/Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis in the US 2004-2008 [585]**
Yu Yan, Dale Q Marmaduke, Simon Voss, Shahab Hasnain. (United States)

- 9 **A Prospective Study of Asthma and Subsequent Use of Hypnotics [586]**
Øystein Karlstad, S Skurtveit, A Tverdal, P Nafstad, K Furu. (Norway)
- 10 **Cataract Is a Frequent Adverse Effect of Widely Used Drugs [587]**
Elena Prokofyeva, Robert Wilke, Eberhart Zrenner. (Germany)
- 11 **Treatment and Characteristics of Thrombotic Thrombocytopenic Purpura in a Managed Care Population [588]**
Peter M Wahl, James N George, Deirdra R Terrell, Amanda Yu, Keith Rodgers, Bruce Ewenstein, Rhonda L Bohn. (United States)
- 12 **Regional Variations in Gaucher Disease Presentation: Data from the ICGG Gaucher Registry [589]**
Neal J Weinreb, Adriana Linares, Hyon Kim, J Alexander Cole, Stephan vom Dahl. (United States)
- 13 **Behavioral Risk Factors among Hispanic and Non-Hispanic White Adults in the United States [590]**
Margaret McDonald, Michael B Lustik. (United States)
- 14 **Characterization of Acetaminophen Overdose-Related Emergency Department Visits and Hospitalizations in the United States [591]**
Angelika Manthripragada, Esther Zhou, Daniel Budnitz, Maribeth Lovegrove, Mary Willy. (United States)
- 15 **Abstract Withdrawn by Author [592]**
- 16 **Prevalence and Incidence of Diabetes Mellitus in Ireland from Prescription Database [593]**
Nur Lisa Zaharan, Kathleen Bennett. (Ireland)
- 17 **Incidence of Diabetic Retinopathy and Diabetic Macular Edema in Newly Diagnosed Type 1 and Type 2 Diabetic Patients [594]**
Elisa Martin-Merino, Joan Fortuny, Estel Plana, Elena Rivero, Luis A Garcia-Rodriguez. (Spain)
- 18 **Urinary Desmosine in Relation to Lung Function – A Study from the Swedish Twin Register [595]**
Gunnar Engström, Claes Lindberg, Kristina Forsman-Semb, Maria Gerhardsson de Verdier, Ulf Nihlén, Magnus Dahlbäck, Henrik Lindberg, Anders Blomgren, Henrik Vissing, Sven Kjellström, Magnus Svartengren, Martin Andersson. (Sweden)
- 19 **Comorbidity Profile of Viral Hepatitis B in a Claims Database [596]**
Michael M Peng, Debra Maldonado, William A Blumentals, Noah Jamie Robinson. (United States)
- 20 **Comorbidity Profile of Viral Hepatitis C in a Claims Database [597]**
Michael M Peng, Debra Maldonado, William A Blumentals, Noah Jamie Robinson. (United States)
- 21 **Prevalence of Depression in Patients with Alzheimer's Disease [598]**
Nataliya Volkova. (United States)
- 22 **Impact of Comorbidities on the Burden for Patients with Parkinson's Disease [599]**
Alex Ward, Shannon L Michels, Stephan Lanes, O'Neill N Gilmore, Papapetropoulos Spyros. (United States)
- 23 **Elevated Risk for Acute Pancreatitis in Type 2 Diabetes Patients Compared to Those without Diabetes [600]**
Tzuyung D Kou, Bing Cai, Charles M Alexander, Debora Williams-Herman, Leonid Katz, Cynthia J Girman. (United States)
- 24 **A Systematic Literature Review and Meta-Analysis of Apolipoprotein E e4 Prevalence in Alzheimer's Disease Patients [601]**
SM Crean, Alex Ward, Catherine J Mercaldi, Jenna M Collins, Michael N Cook, Nicole L Baker, H Michael Arrighi. (United States)
- 25 **Down's Syndrome (DS) in Children, Adolescents and Adults in the UK General Practice Research Database (GPRD): Prevalence and Comorbidities [602]**
Nadia Foskett, Hans Petri, Anthony Amey, Noah Jamie Robinson. (United Kingdom)
- 26 **High Levels of Dispensed Short-Acting beta Agonists in Asthma Patients: Results from the L777 Observational Study [603]**
Laurent Laforest, Samy Boutouaba-Combe, Mélanie Broquet, Véronique Ambrosi, Serge Marvalin, Eric Van Ganse. (France)
- 27 **Association between Bilirubin and Oxidative Stress Mediated Disease [604]**
Laura Horsfall, Greta Rait, Kate Walters, Dallas M Swallow, Stephen P Pereira, Irene Petersen. (United Kingdom)

- 28 Incidence and Prevalence of Endometriosis: Administrative Health Databases Study from Quebec [605]**
Marie-Josée Martel, Nabil Ackad, Jean Lachaine. (Canada)
- 29 What Is the True Prevalence of Knee Osteoarthritis? [606]**
Maria Gerhardsson de Verdier, Gunnar Engström, Jan Rollof, Carl Mellström, Stefan Lohmander. (Sweden)
- 30 Rare Diseases, Orphan Drugs, and the Legislation in China [607]**
YanJun Zhang, Yan-De Zhang, Jing-Bo Wang, Jeff J Guo. (United States)
- 31 A Study of Comorbidities in Multiple Sclerosis [608]**
Cheryl Enger, Michael Doherty, Yvonne Geissbühler, William Collins, John Seeger. (United States)

Cancer and Immunity

- 32 Effectiveness and Patterns of Bortezomib (BTZ) Use in a Real-Life Setting: The VESUVE Cohort Study [609]**
A Fourrier-Reglat, A Grelaud, J Benichou, A Monnereau, M Sturkenboom, M Rouyer, E Bignon, J Jove, N Moore, and the Vesuve Study Group. (France)
- 33 Incidence of Brain Metastases and Hemorrhage among Lung Cancer Patients: A Systematic Review [610]**
Sonia S Maruti, E Dawn Flick, Leanne Houweling, Myrthe PP van Herk-Sukel, Wei Dong. (United States)
- 34 Incidence of Thyroid Hormone Therapy in Patients Treated with Sorafenib or Sunitinib [611]**
Katrin Schuessel, Sandra Feldt, Renate Quinzler, Sittah Czeche, Alexandra Franzmann, Wolf-Dieter Ludwig, Martin Schulz. (Germany)
- 35 Resection of Colorectal Cancer (CRC) Metastases after Bevacizumab (BV) Treatment for 1st-Line Therapy: The ETNA Cohort Study [613]**
A Fourrier-Reglat, M Rouyer, J Benichou, A Balestra, R Lassalle, A Grelaud, D Smith, A Ravaud, N Moore, and the ETNA Group. (France)
- 36 Safety of Two Forms of L-Asparaginase in a Children Cohort with Acute Lymphoblastic Leukemia [614]**
Heilani K Szejnman, Martine Munzer, Marion T Lafaurie, Frédéric Burde, Thierry P Trenque. (France)

- 37 Comorbidity Among Hormone Resistant Prostate Cancer Patients in the US [615]**
Claudia Cabrera, Ceri Hirst, Cortney Hayfinger, Linda Koo. (Sweden)
- 38 Bone Marrow Reticulin and Collagen Content in Patients with Adult Chronic Idiopathic Thrombocytopenic Purpura (cITP): A Danish Nationwide Study [616]**
Mette Nørgaard, Marianne Schmidt Ettrup, Sean Zhao, Preben Johansen, Henrik Toft Sørensen. (Denmark)
- 39 Analysis of Patient Exposure to Vectibix Based on the IntrinsicQ Database [617]**
Fei Xue, Daniel Blaney, Julie Moloney, Victor Gastanaga, Jason Yuan, Scott Stryker, Gail Hughes, Deborah Arrindell, Sean Zhao. (United States)
- 40 Use and Costs of Oral Anticancer Drugs (ATC L01) in the Netherlands from 2000 to 2008 [618]**
Lonneke Timmers, Jan-Jacob Beckeringh, Myrthe PP van Herk-Sukel, Epie Boven, Jaqueline G Hugtenburg. (Netherlands)
- 41 Colorectal Cancer Incidence on the GPRD [619]**
Rachel Charlton, Julia Snowball, Corinne de Vries. (United Kingdom)
- 42 Survival by Anatomic Site, Histologic Type and Tumor Stage in Stomach Cancer Patients from the U.S. SEER Cancer Registry [620]**
Lisa Wang, Laura Chu, Mona Shing, Wei Dong. (United States)

Cardiovascular

- 43 Abstract Withdrawn by Author [621]**
- 44 Statin-Associated Total Cholesterol Concentration Change and Outcome of Cardiovascular Event among Chronic Kidney Disease Patients: A Population-Based Cohort Study [622]**
Xia Sheng, Li Wei, Thomas M MacDonald. (United Kingdom)
- 45 Dual Antiplatelet Therapy Benefited the Patients Received Percutaneous Coronary Intervention in Taiwan [623]**
Chia-Hsien Chang, Yea-Huei Kao Yang. (Taiwan)
- 46 Abstract Withdrawn by Author [624]**

- 47 Drug Utilization Review of Antihypertensive Therapy among Patients with Compelling Indications in Two Hospitals in South-Eastern Nigeria [625]**
Obinna Ikechukwu Ekwunife, Chukwuemeka Micheal Ubaka. (Nigeria)
- 48 Hypertension Management Is Suppressed by the Start of Diabetes Drugs [626]**
Jaco Voorham, Flora M Haaijer-Ruskamp, Bruce H Wolffenbuttel, Ronald P Stolk, Petra Denig. (Netherlands)
- 49 Incidence of Hospitalized Rhabdomyolysis with Statin and Fibrate Use in an Insured US Population [627]**
Kandace L Amend, Joan Landon, Steve J Niemcryk, Andrew McAfee. (United States)
- 50 Statins in the Primary and Secondary Prevention of Cardiovascular Disease among Patients with Rheumatoid Arthritis: A Population-Based Cohort Study [628]**
Xia Sheng, Li Wei, Thomas M MacDonald. (United Kingdom)
- 51 The Impact of Statins on Total Cholesterol Concentration and Risk of Cardiovascular Disease among Patients with COPD: A Population-Based Cohort Study [629]**
Xia Sheng, Li Wei, Thomas M MacDonald. (United Kingdom)
- 52 Risk of Myocardial Infarction in UK Primary Care Patients with Hepatitis C Virus Infection [630]**
Kimberly Forde, Kevin Haynes, James Lewis, Vincent Lo Re. (United States)
- 53 Concomitant Use of Diuretics and Risk of Digoxin Intoxication among Elderly Heart Failure Patients [631]**
Chul Woo Rhee, Dong Yoon Kang, So Young Park, Byung Joo Park. (Republic of Korea)
- 54 Myocardial Infarction and Cerebrovascular Accident in Patients with Retinal Vein Occlusion [632]**
Laura K Chu, Winifred Werther. (United States)
- 55 Pharmacoepidemiology Safety Study of Statin, Fibrate, or Statin-Fibrate Combination Therapy [633]**
Cheryl Enger, Robert Gately, Steve J Niemcryk, Eileen E Ming, Andrew T McAfee. (United States)

- 56 Hyperprolactinemia and Risk of Valvular Heart Disease: A Danish Nationwide Population-Based Cohort Study [634]**
Merete L Dybdal, Jens Otto L Jørgensen, Henrik T Sørensen. (Denmark)
- 57 Prevalence of Atrial Fibrillation (AF) in the US [635]**
Kathy L Schulman, Stephen S Johnston, Jay Lin, Daniel M Huse. (United States)
- 58 Incidence Rates of Retinal Artery Thrombosis in Solid Tumor Cancer Patients in the THIN Database [636]**
Victor Gastanaga, Chuck Wentworth, Gail Hughes, Fei Xue, Vanitha Ganesh, Mukesh Verma, Isaiah Dimery, Sean Zhao. (United States)
- 59 Parameterizing Risk-Benefit Models from Primary Care Data: Recurrence and Exacerbation [637]**
Andrew Maguire, Betina Blak, Kevin Haynes. (United Kingdom)

- 60 Use of Propranolol in Liver Cirrhosis Patient To Prevent Esophageal Varix Bleeding [638]**
Joongyub Lee, Nam-Kyong Choi, Ye-Jee Kim, Ju-young Shin, Byung-Joo Park. (Korea)
- 61 Cardiovascular Events in Statin Recipients: A 3-Year Record-Linkage Study on Prescription and Hospital Discharge Databases [639]**
Elisabetta Poluzzi, Carlo Piccinni, Paolo Carta, Aurora Puccini, Monica Lanzoni, Domenico Motola, Alberto Vaccheri, Fabrizio De Ponti, Nicola Montanaro. (Italy)

CNS

- 62 Defining Persistent Opioid Use from Prescription Registries [640]**
Kristian Svendsen, Olav MS Fredheim, Pål Romundstad, Petter C Borchgrevink, Svetlana Skurtveit. (Norway)

- 63 Hospitalizations Associated with Acetaminophen Poisoning in the United States [641]**
Syed Rizwanuddin Ahmad, Anne Elixhauser. (United States)
- 64 Characteristics of Patients Receiving Varenicline Treatment for Smoking Cessation in UK Primary Care – A THIN Database Study [642]**
Betina T Blak, Koo Wilson, Michael Metcalfe, Michelle Hards, Andrew Maguire, Victoria Gimeno. (United Kingdom)
- 65 Transitions from General Practitioner to Psychiatrist Care (Or Vice Versa) during a First Antidepressant Treatment Episode [643]**
Helga Gardarsdottir, Toine CG Egberts, Eibert R Heerdink. (Netherlands)
- 66 Drug Utilization of Transdermal Fentanyl in Germany [644]**
Ulrike Schmid, Kathrin Jobski, Edeltraut Garbe. (Germany)



ParagonRx
an inVentiv clinical company

Minimizing Risk and Optimizing Use of Medical Products
www.paragonrx.com

*ParagonRx is proud to support the
International Society for Pharmacoepidemiology
in leading the advancement of
drug safety and risk management*

Visit us at booth #29

- 67 Changes in Antidepressant Use Following Regulatory Agency Advisories [645]**
Amanda R Patrick, Colin R Dormuth, Sebastian Schneeweiss. (United States)
- 68 Pattern of Triptan Use in a Sample of the Italian General Population [646]**
Chiara Biagi, Elisabetta Poluzzi, Domenico Motola, Giuseppe Roberto, Aurora Puccini, Alberto Vaccheri, Roberto D'Alessandro, Nicola Montanaro. (Italy)
- 69 Composite Data-Mining Index for Signal Detection Using Healthcare Claims Database: Methylphenidate Safety as an Example [647]**
Jong-Mi Seong, Nam-Kyong Choi, Yunhee Choi, Ye-Jee Kim, Joongyub Lee, Jin Ho Lee, Byung-Joo Park. (Republic of Korea)
- 70 Factors Associated with the Schizophrenia Specific States: A Population-Based Study [648]**
Alice Dragomir, Ridha Joobier, Jean-Francois Anngers, Jean-Eric Tarride, Sylvie Perreault. (Canada)
- 71 Risk of Cardiac Valve Regurgitation with Dopamine Agonist Use in Parkinson's Disease and Hyperprolactinemia [650]**
G Trifirò, M Mokhles, J Dieleman, E van Soest, G Mazzaglia, R Herings, C de Luise, D Ross, G Brusselle, A Colao, W Haverkamp, R Schade, G van Camp, R Zanettini, M Sturkenboom. (Netherlands)
- 72 Abstract Withdrawn by Author [651]**
- 73 Antipsychotics and Diabetes: Does Effect Differ by Dose? [652]**
H Dakki, M Ulicikas Yood, G DeLorenze, C P Quesenberry Jr, S A Oliveria, A Tsai, E Kim, M Cziraky, J W Newcomer, G J L'talien. (United States)
- 74 Cause of Death in Patients with Multiple Sclerosis and Controls: The General Practice Research Database [653]**
Arief Lalmohamed, Marloes T Bazelier, Tjeerd P van Staa, Frank de Vries. (Netherlands)
- 75 Association of Handgrip Strength with Dementia in a Korean Elderly Population [654]**
Hee-Young Shin, Jae-Min Kim, Il-Seon Shin, Jin-Sang Yoon. (Korea)
- 76 Prevalence of Alcohol Related Disorders in German Patients Treated with High-Potency Opioids [655]**
Ulrike Schmid, Sigrid Behr, Kathrin Jobski, Frank Andersohn, Edeltraut Garbe. (Germany)
- 77 The Prevalence of Depressive Symptoms and the Effects of Antidepressants in Patients with Psychotic Disorders in Routine Clinical Practice [656]**
Katja Taxis, Irene Lako, Richard Bruggeman, Rikus Knegtering, Dirk Wiersma, Cees Slooff. (Netherlands)
- 78 Association between LEP- and LEPRGene Polymorphisms and Dyslipidemia in Patients Using Atypical Antipsychotic Medication [657]**
Jochem G Gregoor, Jan van der Weide, Harriet M Looovers, Harold J van Megen, Toine C Egberts, Eibert R Heerdink. (Netherlands)
- 79 Abstract Withdrawn by Author [658]**
- 80 A Descriptive Analysis of Acetaminophen Poisoning in the U.S. Military Health Care System [659]**
Lockwood Taylor, Suji Xie, Paula Doulaveris, Trinka Coster. (United States)
- 81 Can a Drug Have Better Results in the 'Real World'? A Case Study of Cholinesterase Inhibitors in Australia [660]**
Maxine Robinson, Kerry Atkins, Ann Leverton. (Australia)
- 82 Prevalence Rates of Comorbidities in Patients with Multiple Sclerosis [661]**
Wendy J Carman, Andrew T McAfee, Julia LaGuette, Shuhua Su, Darryl Chiu. (United States)
- 83 Observational Assessment of Safety in Seroquel XL (OASIS) Study: Design and Rationale of a Non-Randomised Observational Safety Study [662]**
Deborah Layton, Vanessa Marshall, Sarah Clarke, Saad Shakir, Tony Hale. (United Kingdom)
- 84 Prescription Patterns among Children with Attention Deficit Hyperactivity Disorder (ADHD) in the United Kingdom (UK) [663]**
Sudha R Raman, Stephen W Marshall, Til Stürmer. (United States)
- 85 Patient Reports of Antipsychotic-Induced Depressive Symptoms – A Cross Sectional Study in Patients with Psychotic Disorders [664]**
Irene M Lako, Huib Burger, Rikus Knegtering, Richard Bruggeman, Katja Taxis. (Netherlands)
- 86 Age Related Differences in Antidepressant Prescribing [665]**
Thibaut Sanglier, Dominique Milea, Delphine Saragoussi, Jean-Paul Auray, Marie Tournier, RJ Valuck. (France)
- 87 Prescribing Behaviour of Smoking Cessation Products in the UK – A THIN Database Study [666]**
Betina T Blak, Michelle Hards, Hassy Dattani, Mary Thompson. (United Kingdom)
- 88 Antidiabetic Treatment in Japanese Psychotic Inpatients [667]**
Ataru Inagaki, Toshiaki Itoh, Kazumi Tsukada. (Japan)
- 89 Pediatric Atypical Antipsychotic Out-patient Drug Utilization in the US: Y2002 – Y2009 [668]**
Grace P Chai, Hina Mehta, Laura Governale. (United States)
- 90 The Feasibility of Monitoring Paediatric Adverse Drug Reactions (ADRs) Via Specialist Clinics [669]**
Mansour Tobaigy, Derek Stewart, Peter J Helms, James McLay. (United Kingdom)
- 91 Frequency and Predictors of Anti-Epileptic Drug Regimen Change in an Incident Epilepsy Cohort [670]**
Marianne C Cunningham, David J Webb, Ranjani Munjanath. (United Kingdom)
- 92 Effect of Selective Serotonin Re-Uptake Inhibitors on Myocardial Infarction: A Systematic Review [671]**
Ye-Jee Kim, Nam-Kyong Choi, Joongyub Lee, Chul Woo Rhee, So Young Park, Byung-Joo Park. (Republic of Korea)
- 93 Evaluation of Cardiovascular Diseases (CVDs) Risk for Patients with Fibromyalgia Syndrome in the United States [672]**
P J Mease, M S Duh, F Vekeman, P Lefebvre, F Laliberté, M Boerstoele-Streefland, W Jiang, P J Zimetbaum. (United States)
- 94 Prevalence Rate Ratios of Comorbidities and Symptoms in Patients with MS Compared to the General Population, Stratified by Treatment Group [673]**
Wendy J Carman, Andrew T McAfee, Julia LaGuette, Shuhua Su, Darryl Chiu. (United States)
- 95 Changes in Prevalence of Comorbidities and Symptoms among MS Patients by Treatment Group [674]**
Wendy J Carman, Andrew T McAfee, Julia LaGuette, Shuhua Su, Darryl Chiu. (United States)
- 96 Selected Opioid Use in Medicare Part D and Medicaid Elderly [675]**
Rita Ouellet-Hellstrom, Fatmatta Kuyateh, Farzana Ali, Emily Singer, Thomas E MacCurdy, David J Graham. (United States)

Drug Utilization Research/ Health Services Research

- 97 Methylphenidate Treatment in Children and Adolescents with Attention Deficit/Hyperactivity Disorder (ADHD): A Drug Utilization Study in a US Database [676]**
Yvonne Geissbühler, Estel Plana, Catherine Tuvblad. (Switzerland)
- 98 Potentially Inappropriate Medication (PIM) Prescribing in Elderly Outpatients: An Evaluation of Claims Data Based on the Beers Criteria [677]**
Martin Huber, Gerd A Kullak-Ublick, Wilhelm Kirch. (Germany)
- 99 Chronic Consumption of Antipsychotic Drugs in Belgian Nursing Home Residents [678]**
Majda Azermai, Robert Vander Stichele, Monique Elseviers, Mirko Petrovic, Luc Van Bortel. (Belgium)
- 100 Factors Associated with Potential Drug Interactions in an Intensive Care Unit [679]**
Adriano Max M Reis, Silvia Helena De B Cassiani. (Brazil)
- 101 When Inappropriate Medications Are Medically Justified in the Elderly [680]**
ML Laroche, S Crépin, S Allouetteau, JP Charmes, L Merle. (France)
- 102 Generic Switching Does Not Influence Patients' Concerns about Medicines. A Prescription Database and Questionnaire Study [681]**
Morten Andersen, Karen Elberg, Annette Foged, Dorte G Hansen, Jesper Hallas, Jens Soendergaard. (Denmark)
- 103 The Pattern of Use of Anti-Depressant Drugs [682]**
Sandra López-León, Joan Fortuny, Estel Plana, Elena Rivero. (Spain)
- 104 The Impact of Withdrawal Rofecoxib on NSAIDs Utilization [683]**
J Atthobari, C Boersma, S T Visser, M J Postma, L TW de Jong-van den Berg. (Indonesia)
- 105 Abstract Withdrawn by Author [684]**
- 106 Chronic Benzodiazepine Consumption in Belgian Nursing Home Residents [685]**
Majda Azermai, Robert Vanderstichele, Monique Elseviers, Mirko Petrovic, Luc Van Bortel. (Belgium)

- 107 Economic Burden of Drug Interactions Among Hospitalized Patients [686]**
Cristiano S Moura, Priscila L Guimarães, Jéssica O Bomfim, Francisco A Acurcio. (Brazil)
- 108 GP's Opinions of the Hospital Discharge Notes – A Survey among GPs [687]**
Anne K Eek, Hege S Blix, Kirsten K Viktil, Trond Moger, Aasmund Reikvam. (Norway)
- 109 Oral Immunosuppressive Drug Utilization and Costs in the U.S. Medicaid Programs: A Trend Analysis from 1991 to 2007 [688]**
Yan-Jun Zhang, Jing-Bo Wang, Jeff J Guo, Christina ML Kelton, Teresa Cavanaugh. (United States)
- 110 Does a National Medicines Policy Improve Medicines Access and Utilisation? [689]**
Lisa G Pont, Anna Kemp, Elizabeth E Roughead. (Australia)
- 111 Disease-Specific Healthcare Utilization Following Implementation of a Therapeutic Interchange Program [690]**
Thomas K Hazlet, Srikanth Kadiyala, Stanley Gu, Elizabeth B James. (United States)
- 112 Is There an Underconsumption of Antidepressants in Nursing Home Residents? [691]**
Majda Azermai, Robert Vander Stichele, Monique Elseviers, Mirko Petrovic, Luc Van Bortel. (Belgium)
- 113 Increase in Use of Hypnotic Drugs among Children and Adolescents Aged 0-17 Years – A Nationwide Prescription Database Study [692]**
Ingeborg Hartz, Kari Furu, Bratlid Trond, Svetlana Skurtveit. (Norway)
- 114 Association between Prescribing Procedure and Rate of Revaluation [693]**
Christina Sjöberg, Susanna M Wallerstedt. (Sweden)
- 115 Abstract Withdrawn by Author [694]**
- 116 Representativity of Dispensations of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) in the German Pharmacoepidemiological Research Database [695]**
Tania Schink, Edeltraut Garbe. (Germany)
- 117 The Effects of E-Prescribing on Generic Drug Utilization and Drugs Costs in the Ambulatory Care Setting: A Quasi Experimental [696]**
J Atthobari, E B Sulistiyanto. (Indonesia)

Gut

- 118 Metformin Associated Lactacidosis – An Increasing Problem? [697]**
Steinar Madsen, Tanja Holstad. (Norway)
- 119 Reflux Disease, Gastrointestinal Ulcer or Weight Loss in Patients with COPD [698]**
Cornelia Schneider, Susan S Jick, Ulrich Bothner, Christoph R Meier. (Switzerland)
- 120 Diabetes Mellitus and Risk of Gallstone Disease Followed by Cholecystectomy [699]**
Patrick Imfeld, Michael Bodmer, Yolanda B Brauchli, Stephan Krähenbühl, Susan S Jick, Christoph R Meier. (Switzerland)
- 121 Analysis of Suspected Adverse Reactions to Antidiabetic Drugs Spain, 2008 [700]**
Maria-Isabel Jimenez-Serrania, Ramona Mateos-Campos. (Spain)
- 122 Assessing Non-Serious Adverse Drug Events in Observational Studies among Type 2 Diabetes Mellitus Patients: A Review of Methods Used [701]**
L Hakobyan, FM Haaijer-Ruskamp, D Dobre, D de Zeeuw, P Denig. (Netherlands)
- 123 Utilization Study of Antidiabetic Drugs in Spain, 2008 [702]**
Maria-Isabel Jimenez-Serrania, Ramona Mateos-Campos. (Spain)
- 124 Drug-Related Upper Gastrointestinal Bleeding: Comparison of Signal Detection Results between Spontaneous Reporting and Longitudinal Healthcare Databases [703]**
Vaishali Patadia, Rosa Gini, Ron Herings, Giampiero Mazzaglia, Gino Picelli, Lorenza Scotti, Lars Pedersen, Johan van der Lei, Miriam Sturkenboom, Gianluca Trifirò. (United States)

Medications in Pregnancy

- 125 Strategies for Analyzing Multiple Gestations and Sequential Pregnancies in Pregnancy Registries [704]**
Deborah Covington, Amanda Golembesky, Carl deMoor. (United States)
- 126 Impact Evaluation of Intermittent Preventive Treatment Implementation for Malaria during Pregnancy in Omdurman-Sudan IDP Camp 2006 [705]**
Ahmed Eisa Saeed. (Sudan)

POSTER SESSION C Sunday, August 22

127 Medication Exposure in Pregnancy Risk Evaluation Program [706]
Susan Andrade, Pamela Scott, Craig Cheetham, William Cooper, Robert Davis, De-Kun Li, Sascha Dublin, Pamala Pawloski, Marsha Raebel, Darren Toh. (United States)

128 Methodological Challenges in Evaluating Long-Term Safety of Quinacrine Non-Surgical Sterilization [707]
Jie Li, Judith K Jones, Arlene Tave, John C Pezzullo. (United States)

129 Global Prevalence of Pregnancy Outcomes [708]
Melissa Whipple Neibauer, Matthew Reynolds, Shannon L Michels, Jenna Collins. (United States)

130 A Claims-Based Algorithm To Estimate the Date of the Last Menstrual Period [709]
Andrea V Margulis, Soko Setoguchi, Sonia Hernández-Díaz. (United States)

131 A Preliminary Assessment of Health Care Databases Potentially Available for the Drug Safety Research in Pregnancy [710]
Wendy Camelo-Castillo, Irini-Alexia Terzakis, Susan S Roberts. (United States)

132 Prevalence and Predictors of Complementary and Alternative Medicine Products Use Among Pregnant Women in New Mexico [711]
Ludmila N Bakhireva, Preeyaporn Sarangarm, Sizhu Liu, Bonnie N Young, Anne Davis, Jean T Cox, Sharon T Phelan, William F Reyburn. (United States)

133 A Database-Driven Adverse Drug Reactions Detection Method – A Pilot Test with Three Illustrative Cases [712]
Man Young Park, Dukyong Yoon, KiYoung Lee, Rae Woong Park. (Republic of Korea)

134 Trends of the Medical Consumption of Benzodiazepines during Years 2003 to 2007 in Taiwan and Preliminary Cross-National Comparisons [713]
Ching-Hsing Chang, Jiin-Shain Lai, Chun-Sheng Chien, Jaw-Jou Kang. (Taiwan)

135 Innovative Signal Detection: Optimization of Empirica Signal – A Case Study [714]
Conny Berlin, Carles Blanch, David Lewis, Michel Petrin, Dionigi Maladorno, Severine Sarp, Christiane Michel, Philippe Close. (Spain)

136 Can Data Mining Spontaneously Reported Adverse Events Be Used To Assess Drug Abuse Potential [715]
Cynthia Arons, Eric Hung, Sian Ratcliffe, Doug Feltner, Manfred Hauben. (United Kingdom)

137 Identification and Characterization of Cancer Patients Using Health Insurance Database [716]
Fei Xue, Jason Yuan, Deborah Arrindell, Sean Zhao. (United States)

Methods



We discover the value within.

IMS helps you realize the potential of your products.

Combining commercial insight with scientific evidence is required to maximize market access. That's why IMS has built a global team of more than 300 experts in Pricing, Local Market Access, and Health Economics and Outcomes Research and the world's most extensive databases.

Our team combines rigorous scientific research — evidenced by more than 350 publications since 2008 — with commercially savvy consulting to help determine, demonstrate, communicate and realize product value.

We have unparalleled claims, medical, hospital and patient-centered pharmaceutical databases. Our HEOR experts use them to create an Evidence-Based ConsultingSM powerhouse.

So the next time you're thinking about product value, find out what we're thinking.

Contact our consulting team at +1.703.286.2900 or visit www.imshealth.com/heor

ims

INTELLIGENCE.
APPLIED.

© 2010 IMS Health Incorporated or its affiliates. All rights reserved.

- 138 Use of a Ranking Statistic To Assess Pharmacovigilance Data Mining Algorithms [717]**
Stephanie Reisinger, Manfred Hauben, Alan Hochberg, Ronald K Pearson. (United States)
- 139 Identifying Early Presentation of Multiple Sclerosis: A Challenge Using Insurance Claims Data [718]**
Suellen M Curkendall, Cheng Wang, Barbara H Johnson, Ronald Preblich, Amelito Torres, Volker Knappertz, Kathleen Gondek. (United States)
- 140 Prospective, Active Surveillance for Medication Safety in Population-Based Health Networks: A Pilot Study [719]**
Taliser R Avery, Yury Vilks, Martin Kulldorff, Lingling Li, T Craig Cheetham, Sascha Dublin, John Hsu, Robert L Davis, Liyan Liu, Richard Platt, Jeffrey S Brown. (United States)
- 141 Potentially Inappropriate Drug Prescription in the Elderly in France: Results from the EGB Database [720]**
ML Laroche, B Bongué, S Gutton, L Merle, A Colvez. (France)
- 142 Automated Method for Detecting Temporal Changes in Spontaneous AE Data [721]**
Nancy Yuen, Nassrin Payvandi, Wendy Booth, June Almenoff, David Fram, William DuMouchel. (United States)
- 143 Abstract Withdrawn by Author [722]**
- 144 Drug Purchases during Pregnancy in Finland, 1996-2006: Focus on Antidepressants [723]**
Miia Artama, Heli Malm, Mika Gissler, Annukka Ritvanen, Drugs and Pregnancy Group. (Finland)
- 145 Establishing Drug-Era Persistence Window for Active Surveillance [724]**
Abraham Hartzema, Patrick Ryan, Paul Stang, Judy Racoosin, Marc Overhage. (United States)
- 146 Completeness of Laboratory Data in a U.S. Claims Database [725]**
Laura N Horne, Charles Doyle, Krista M Schladweiler, Eileen E Ming. (United States)
- 147 A Sorting and Classification Method for Interactive Visualization of Drug/Event Patterns across Many Patient Timelines [726]**
Sigfried Gold, Suji Xie, Lockwood Taylor, Ana Szafrman, Trinka Coster. (United States)
- 148 Chiral Pharmacovigilance: Spontaneous Reporting Profiles of Racemates vs. Enantiomers [727]**
Manfred Hauben, Meg Richards. (United States)
- 149 Development of Prediction Model for Severity of Adverse Drug Reactions in Hospitalized Patients [728]**
Thiyagu Rajakannan, Laxminarayana K Bairy, Padma GM Rao, Vasudeva Guddattu, SurulivelRajan Mallayasyam. (India)
- 150 Guiding Antibiotic Selection: Differences in Methicillin-Resistant Staphylococcus aureus (MRSA) Rates among Hospitalized and Primary Care Patients [729]**
Jessina C McGregor, David T Bearden, John M Townes, Dale F Kraemer, David H Smith. (United States)
- 151 Users of Preserved Eye Drops: Who Switches to Preservative-Free Alternatives? [730]**
Jakob Petersen, Lesley Wise. (United Kingdom)
- 152 Methods for Assessing the Preventability of Adverse Drug Events – A Systematic Review [731]**
Katja M Hakkarainen, Karolina Andersson, Max Petzold, Staffan Hägg. (Sweden)
- 153 An Algorithm for the Diagnosis of Suicide in the THIN Database [732]**
Alejandro Arana, Felix M Arellano, Charles W Wentworth, Janet Price. (Spain)
- 154 Influence of Selection Criteria on Cohort Characteristics [733]**
Suellen Curkendall, Tami Mark, Huifang Liang, Helga Gardarsdottir. (United States)
- 155 Linking UK Death Certificate Data to UK Primary Care Data (General Practice Research Database) [734]**
Efrosini Setakis, Shivani Puri, Arlene Gallagher, Susan Eaton, Frank DeVries, Tim J Williams, Tjeerd P VanStaa. (United Kingdom)
- 156 Lessons Learned from Mapping the THIN Database to the Observational Medical Outcome Partnership (OMOP) Common Data Model (CDM) [735]**
X Zhou, S Murugesan, C Wentworth, H Bhullar, A Bate. (United States)
- 157 Representiveness of Subset of the General Practice Research Database (GPRD) Linked to Other Data Sources [736]**
Efrosini Setakis, Shivani Puri, Tim J Williams, Tjeerd P VanStaa. (United Kingdom)
- 158 Vaccine Signal Detection: Comparative Results of Several Innovative Data Mining Approaches [737]**
Steven R Bailey, Peter Huber, Robert Azadian. (United States)

Muscles and Bones

- 159 Effects of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) on Blood Pressure in Patients with Hypertension [738]**
Hisham Aljadhey, Michael Murray, D Craig Brater. (Saudi Arabia)
- 160 SALT-I (Study of Acute Liver Transplant): A Study of NSAID-Exposed Acute Liver Failure in European Transplant Centres [739]**
Ezgi Gulmez, Séverine Lignot, Corinne de Vries, Miriam Sturkenboom, Susanna Perez-Gutthann, Jacques Bénichou, Franco Bissoli, Dominique Larrey, Georges Pageaux, Yves Horsmans, Jacques Bernuau, Bruno Stricker, Douglas Thorburn, Patrick Blin, Nicholas Moore. (France)
- 161 A Review of RCTs on the Gastrointestinal and Cardiovascular Safety of NSAIDs in Children: The SOS Project [740]**
M Balzarin, F Salvo, A Fourrier-Réglat, N Moore, M Haag, M Sturkenboom, F Zulian, C Giaquinto, A Pariente. (France)
- 162 Multiple Myeloma and IV Bisphosphonate Are Risk Factors for Osteonecrosis of the Jaw [741]**
Pat Tennis, Kenneth J Rothman, Rhonda Bohn, Hiangkai Tan, Mary Anthony, Athanosios Zavras, Brian Calingaert. (United States)
- 163 The SOS Project: Nonsteroidal Anti-Inflammatory Drugs and Upper Gastrointestinal Complications: Meta-Analysis of Epidemiological Studies [742]**
Nuria Riera-Guardia, Jordi Castellsague, Brian Calingaert, Cristina Varas-Lorenzo, Annie Fourrier-Reglat, Federica Nicotra, Miriam CJM Sturkenboom, Susana Perez-Gutthann. (Spain)
- 164 The Utilization of Biological Agents in Rheumatoid Arthritis Patients in Southern Taiwan [743]**
Hui-Chen Chang, Li-Chia Chen, Jin-Song Wu, Hui-Ling Tseng. (Taiwan)

- 165 Methodological Issues and Knowledge Gaps in RCTs Evaluating the Safety of NSAIDs in Adults: The SOS Project [744]**
F Salvo, A Fourrier-Reglat, M Balzarin, F Bazin, N Riera, M Haag, N Moore, M Sturckenboom, A Pariente. (France)
- 166 Prescribing Trends of Bisphosphonates in General Practice, UK 1995-2008 [745]**
Jakob Petersen, Lesley Wise. (United Kingdom)
- 167 Chronic Use of Non-Steroidal Anti-Inflammatory Drugs and the Risk of Atrial Fibrillation [746]**
Raffaele De Caterina, Ana Ruigómez, Luís Alberto García Rodríguez. (Spain)
- 168 Chemoprevention of Breast Cancer with Bisphosphonates [747]**
Sharon Hensley Alford, Christine Cole Johnson, Stephen B Gruber, Sofia D Merajver. (United States)
- 169 Pattern of Use of NSAIDs in Italian Population and Frequency of Risk Factors for Gastrointestinal Injury [748]**
Chiara Sacripanti, Elisabetta Poluzzi, Alessandra Berti, Elisa Rossi, Marisa De Rosa, Nicola Montanaro. (Italy)
- 170 Factors Associated with Methodological Quality of RCTs Evaluating the Safety of NSAIDs: The SOS Project [749]**
F Salvo, A Fourrier-Réglat, F Bazin, M Balzarin, M Haag, N Moore, M Sturckenboom, A Pariente. (France)
- 175 The Pattern of Drug-Induced Rhabdomyolysis Reports in Taiwan [754]**
Wei-Ming Ke, Wen-Wen Chen, Churn-Shiouh Gau. (Taiwan)
- 176 Multicentre Study on Adverse Drug and Vaccine Reactions in Children during A-H1N1 Virus Pandemic [755]**
Francesca Menniti-Ippolito, Roberto Da Cas, Concita Rafaniello, Giuseppe Traversa, Multicenter Study Group on Safety of Drugs and Vaccines in Children. (Italy)
- 177 Detection of Late Effects of Drugs Children Using a Spontaneous Report ADR Database [756]**
S de Bie, KMC Verhamme, SMJM Straus, GW 't Jong, BHC Stricker, MCJM Sturckenboom. (Netherlands)
- 178 Patient Reporting of ADRs in the UK: How Do Patient Reports Affect Potential Signals Generated by Healthcare Professionals? [757]**
L Hazell, V Cornelius, S Shakir, A Avery. (United Kingdom)
- 179 The Yellow Card Scheme: Experience of Patient Reporting of Adverse Drug Reactions 5 Years Since Launch [758]**
Sarah L Cumber, Sarah J Heffer, Shelley Gandhi, Anthony J Avery. (United Kingdom)
- 180 Spontaneous Reports as a Source for Risk Assessment of Long Term Drug Use in Children [759]**
S de Bie, KMC Verhamme, SMJM Straus, GW 't Jong, BHC Stricker, MCJM Sturckenboom. (Netherlands)
- 184 Pilot Swine Flu Vaccination Active Surveillance Study: Interim Results [763]**
D Layton, D Rutherford, T M MacDonald, S AW Shakir, I S Mackenzie. (United Kingdom)
- 185 Adverse Events Following Bivalent Human Papillomavirus Vaccination Reported to the Enhanced Passive Surveillance System of the Netherlands [764]**
Nicoline van der Maas, Corrie Wesselo, Tieke Phaff, Patricia Vermeer-de Bondt, Bregje Oostvogels. (Netherlands)
- 186 Characteristics of H1N1 Vaccine Exposures in a Large, Commercially Insured Population [765]**
Peter M Wahl, Tao Gu, Gregory W Daniel, Marcus Wilson. (United States)
- 187 Pilot Swine Flu Vaccination Active Surveillance Study: Design and Rationale [766]**
D Layton, D Rutherford, T M MacDonald, S AW Shakir, I S Mackenzie. (United Kingdom)
- 188 Adverse Events of Special Interest (AESI): H1N1 Vaccines Versus Seasonal Influenza Vaccines [767]**
A Hidalgo-Simon, A Segec, J Slattery, A Szmigiel, I Skibicka, J Durand, A Addis, X Kurz. (United Kingdom)
- 189 Interim Results Should Be Taken with Caution: Example of a Vaccine Safety Study [768]**
Patricia Saddier, John Hansen, Michael Emery, Bruce Fireman, Trung Tran, Roger Baxter. (United States)

Pharmacovigilance

- 171 Trends in Reporting of Adverse Drug Reactions to HIV Medicines [750]**
Paul L Barrow, Catherine A King, Jane A Woolley. (United Kingdom)
- 172 Characteristics of Paediatric Individual Case Safety Reports within the WHO-UMC Database [751]**
S de Bie, KMC Verhamme, SMJM Straus, GW 't Jong, BHC Stricker, MCJM Sturckenboom. (Netherlands)
- 173 Differences in Causality Assessments of Adverse Drug Reactions According to the Reports from Different Professional Groups [752]**
Nuno Craveiro, Carlos Alves, Francisco Batel-Marques. (Portugal)
- 174 Topical NSAIDs Adverse Drug Reaction Reports in Thairigibase [753]**
Pakawadee Sriphiromya, Sareeya Wechwiathan. (Thailand)

Vaccines

- 181 Importance of Medical Record Review for Database Studies: Example of Febrile Convulsion (FC) [760]**
Patricia Saddier, Trung Tran, Bradley Ackerson, Lina Sy, Janis Yao, Craig Cheatham, Steven Jacobsen. (United States)
- 182 Reactogenicity of the Bivalent Human Papillomavirus Vaccine [761]**
Jeanet M Kemmeren, Nicoline AT van der Maas, Hester E de Melker. (Netherlands)
- 183 Risk of Incident Autoimmune Diseases after Hepatitis B Vaccination – A Large Cohort Study in the GPRD [762]**
Marco Egbring, Gerd A Kullak-Ublick, Stefan Russmann. (Switzerland)
- 190 Safety of a Monovalent 2009 Influenza A (H1N1) Vaccine in Adult and Pediatric Clinical Trial Populations [769]**
A Graves Jones, S Bassal, P Thomas, M Greenberg, G Hartel, D Washington. (Australia)
- 191 Postmarketing Safety Review for Rotarix®: Data from the Vaccine Adverse Event Reporting System (VAERS), April 2008-October 2009 [770]**
Wei Hua, Rosemary Tiernan, Amy Steffey, David Martin, Robert Wise. (United States)
- 192 Risk of Guillain-Barré Syndrome and Vaccination Against Seasonal Flu [771]**
Lamia Grimaldi-Bensouda, Michel Rosignol, Laurent Magy, Anne Cosson, Lucien Abenheim. (France)

KANTAR HEALTH



Who is Kantar Health?

Kantar Health, a global consultancy and marketing insights organization, delivers value to our clients in the life sciences industry through four globally integrated practice areas: Treatment Value, Commercial Development, Brand and Stakeholder Management, and Marketing Insights.

Formed in 2009 by uniting Consumer Health Sciences, MattsonJack, TNS Healthcare, and Ziment, Kantar Health is the next-generation decision-support partner, delivering evidence-based guidance to accelerate clients' global and local success.

Come by our booth – #25 – to learn more about our gold-standard databases: Epi Database, Epi Database BRIC, CancerMPact, National Health and Wellness Survey, and custom epidemiology and safety capabilities.

Inspired by

Consumer Health Sciences
MattsonJack
TNS Healthcare
Ziment

www.kantarhealth.com

ABSTRACT INDEX Final Program

Abstract #	Poster #	Presentation Time	Room	Format
Friday, August 20				
1		9:00 AM	Clarence	Oral
2		9:15 AM	Clarence	Oral
6		9:30 AM	Clarence	Oral
4		9:45 AM	Clarence	Oral
5		10:00 AM	Clarence	Oral
3		10:15 AM	Clarence	Oral
7		9:00 AM	Dukes	Oral
8		9:15 AM	Dukes	Oral
9		9:30 AM	Dukes	Oral
10		9:45 AM	Dukes	Oral
11		10:00 AM	Dukes	Oral
12		10:15 AM	Dukes	Oral
13		9:00 AM	Hall 4	Oral
14		9:15 AM	Hall 4	Oral
15		9:30 AM	Hall 4	Oral
16		9:45 AM	Hall 4	Oral
17		10:00 AM	Hall 4	Oral
18		10:15 AM	Hall 4	Oral
19		9:00 AM	Buckingham	Oral
20		9:15 AM	Buckingham	Oral
21		9:30 AM	Buckingham	Oral
22		9:45 AM	Buckingham	Oral
557		10:00 AM	Buckingham	Oral
24		10:15 AM	Buckingham	Oral
25		9:00 AM	Balmoral	Oral
26		9:15 AM	Balmoral	Oral
345		9:30 AM	Balmoral	Oral
28		9:45 AM	Balmoral	Oral
29		10:00 AM	Balmoral	Oral
30		10:15 AM	Balmoral	Oral
31		9:00 AM	Cambridge	Oral
32		9:15 AM	Cambridge	Oral
33		9:30 AM	Cambridge	Oral
34		9:45 AM	Cambridge	Oral
35		10:00 AM	Cambridge	Oral
36		10:15 AM	Cambridge	Oral
Methodological Challenges in Cross-National Comparisons of Drug Utilization (Drug Utilisation / Health Services Research SIG Symposium)				
37		3:30 PM	Balmoral	Sympos.
Methodological Controversies from Comparative Effectiveness (CE) Studies Using Claims vs. Electronic Health Record (EHR) Data				
38		3:30 PM	Cambridge	Sympos.
Ascertaining the Use of Biologics (Biologics SIG Symposium)				
39		3:30 PM	Dukes	Sympos.
Guidance Regarding the Identification, Development, Validation and Translation of Coding Algorithms in Electronic Healthcare (EH) Databases (Database SIG Symposium)				
40		3:30 PM	Hall 4	Sympos.
Identifying the Genetic Basis of Serious Adverse Events: Will High-Profile Genome-Wide Association (GWA) Studies Improve Drug Safety in the Next Decade? (A Joint MEBPharmacogenomics-SIG & iSAEC Symposium)				
41		3:30 PM	Buckingham	Sympos.

Abstract #	Poster #	Presentation Time	Room	Format
Friday, August 20 ...continued				
Identification and Classification of Birth Defects in Pharmacoepidemiology: A Comparison of Approaches (Medications in Pregnancy SIG Symposium)				
42		3:30 PM	Clarence	Sympos.
The Public Health Burden of Acetaminophen Poisonings: Risk Management Efforts To Mitigate it				
575		3:30 PM	Ambassador	Sympos.
Poster Session A				
Anti-infectives				
43	1	7:30 AM - 6:00 PM		Poster
44	2	7:30 AM - 6:00 PM		Poster
45	3	7:30 AM - 6:00 PM		Poster
46	4	7:30 AM - 6:00 PM		Poster
47	5	7:30 AM - 6:00 PM		Poster
Blood				
48	6	7:30 AM - 6:00 PM		Poster
49	7	7:30 AM - 6:00 PM		Poster
50	8	7:30 AM - 6:00 PM		Poster
51	9	7:30 AM - 6:00 PM		Poster
52	10	7:30 AM - 6:00 PM		Poster
53	11	7:30 AM - 6:00 PM		Poster
54	12	7:30 AM - 6:00 PM		Poster
55	13	7:30 AM - 6:00 PM		Poster
56	14	7:30 AM - 6:00 PM		Poster
Cancer and Immunity				
57	15	7:30 AM - 6:00 PM		Poster
58	16	7:30 AM - 6:00 PM		Poster
59	17	7:30 AM - 6:00 PM		Poster
60	18	7:30 AM - 6:00 PM		Poster
61	19	7:30 AM - 6:00 PM		Poster
62	20	7:30 AM - 6:00 PM		Poster
63	21	7:30 AM - 6:00 PM		Poster
64	22	7:30 AM - 6:00 PM		Poster
65	23	7:30 AM - 6:00 PM		Poster
Cardiovascular				
66	24	7:30 AM - 6:00 PM		Poster
67	25	7:30 AM - 6:00 PM		Poster
68	26	<i>Abstract Withdrawn by Author</i>		
69	27	7:30 AM - 6:00 PM		Poster
70	28	7:30 AM - 6:00 PM		Poster
71	29	7:30 AM - 6:00 PM		Poster
72	30	7:30 AM - 6:00 PM		Poster
73	31	7:30 AM - 6:00 PM		Poster
74	32	7:30 AM - 6:00 PM		Poster
75	33	<i>Abstract Withdrawn by Author</i>		
76	34	7:30 AM - 6:00 PM		Poster
77	35	7:30 AM - 6:00 PM		Poster
78	36	7:30 AM - 6:00 PM		Poster
79	37	7:30 AM - 6:00 PM		Poster
80	38	7:30 AM - 6:00 PM		Poster
81	39	7:30 AM - 6:00 PM		Poster
82	40	7:30 AM - 6:00 PM		Poster
83	41	7:30 AM - 6:00 PM		Poster

ABSTRACT INDEX Final Program

Abstract #	Poster #	Presentation Time	Room	Format
Friday, August 20 ...continued				
84	42	7:30 AM - 6:00 PM		Poster
85	43	<i>Abstract Withdrawn by Author</i>		
86	44	7:30 AM - 6:00 PM		Poster
87	45	<i>Abstract Withdrawn by Author</i>		
88	46	7:30 AM - 6:00 PM		Poster
89	47	7:30 AM - 6:00 PM		Poster
90	48	7:30 AM - 6:00 PM		Poster
Classical Pharmacoepidemiology				
91	49	7:30 AM - 6:00 PM		Poster
92	50	7:30 AM - 6:00 PM		Poster
93	51	7:30 AM - 6:00 PM		Poster
94	52	7:30 AM - 6:00 PM		Poster
95	53	7:30 AM - 6:00 PM		Poster
96	54	7:30 AM - 6:00 PM		Poster
97	55	7:30 AM - 6:00 PM		Poster
98	56	7:30 AM - 6:00 PM		Poster
99	57	7:30 AM - 6:00 PM		Poster
100	58	7:30 AM - 6:00 PM		Poster
101	59	7:30 AM - 6:00 PM		Poster
CNS				
102	60	7:30 AM - 6:00 PM		Poster
103	61	7:30 AM - 6:00 PM		Poster
105	62	7:30 AM - 6:00 PM		Poster
106	63	7:30 AM - 6:00 PM		Poster
107	64	7:30 AM - 6:00 PM		Poster
108	65	7:30 AM - 6:00 PM		Poster
109	66	7:30 AM - 6:00 PM		Poster
110	67	7:30 AM - 6:00 PM		Poster
111	68	7:30 AM - 6:00 PM		Poster
112	69	7:30 AM - 6:00 PM		Poster
113	70	7:30 AM - 6:00 PM		Poster
114	71	7:30 AM - 6:00 PM		Poster
115	72	7:30 AM - 6:00 PM		Poster
117	73	7:30 AM - 6:00 PM		Poster
658	74	7:30 AM - 6:00 PM		Poster
Drug Utilization Research/Health Services Research				
118	75	<i>Abstract Withdrawn by Author</i>		
119	76	7:30 AM - 6:00 PM		Poster
120	77	7:30 AM - 6:00 PM		Poster
121	78	7:30 AM - 6:00 PM		Poster
122	79	7:30 AM - 6:00 PM		Poster
123	80	7:30 AM - 6:00 PM		Poster
124	81	7:30 AM - 6:00 PM		Poster
125	82	7:30 AM - 6:00 PM		Poster
126	83	7:30 AM - 6:00 PM		Poster
127	84	7:30 AM - 6:00 PM		Poster
128	85	7:30 AM - 6:00 PM		Poster
129	86	7:30 AM - 6:00 PM		Poster
130	87	7:30 AM - 6:00 PM		Poster
131	88	7:30 AM - 6:00 PM		Poster
132	89	7:30 AM - 6:00 PM		Poster
133	90	7:30 AM - 6:00 PM		Poster
134	91	7:30 AM - 6:00 PM		Poster
135	92	7:30 AM - 6:00 PM		Poster
136	93	7:30 AM - 6:00 PM		Poster

Abstract #	Poster #	Presentation Time	Room	Format
Friday, August 20 ...continued				
Gut				
137	94	7:30 AM - 6:00 PM		Poster
138	95	7:30 AM - 6:00 PM		Poster
139	96	7:30 AM - 6:00 PM		Poster
140	97	7:30 AM - 6:00 PM		Poster
141	98	7:30 AM - 6:00 PM		Poster
142	99	7:30 AM - 6:00 PM		Poster
143	100	7:30 AM - 6:00 PM		Poster
144	101	7:30 AM - 6:00 PM		Poster
145	102	7:30 AM - 6:00 PM		Poster
146	103	7:30 AM - 6:00 PM		Poster
Lungs				
147	104	7:30 AM - 6:00 PM		Poster
148	105	7:30 AM - 6:00 PM		Poster
149	106	7:30 AM - 6:00 PM		Poster
150	107	7:30 AM - 6:00 PM		Poster
151	108	7:30 AM - 6:00 PM		Poster
152	109	7:30 AM - 6:00 PM		Poster
153	110	7:30 AM - 6:00 PM		Poster
154	111	7:30 AM - 6:00 PM		Poster
Medications in Pregnancy				
155	112	7:30 AM - 6:00 PM		Poster
156	113	7:30 AM - 6:00 PM		Poster
157	114	7:30 AM - 6:00 PM		Poster
158	115	7:30 AM - 6:00 PM		Poster
159	116	7:30 AM - 6:00 PM		Poster
160	117	7:30 AM - 6:00 PM		Poster
161	118	7:30 AM - 6:00 PM		Poster
162	119	7:30 AM - 6:00 PM		Poster
163	120	7:30 AM - 6:00 PM		Poster
164	121	7:30 AM - 6:00 PM		Poster
165	122	7:30 AM - 6:00 PM		Poster
166	123	7:30 AM - 6:00 PM		Poster
167	124	7:30 AM - 6:00 PM		Poster
Methods				
168	125	7:30 AM - 6:00 PM		Poster
169	126	7:30 AM - 6:00 PM		Poster
170	127	7:30 AM - 6:00 PM		Poster
171	128	7:30 AM - 6:00 PM		Poster
172	129	7:30 AM - 6:00 PM		Poster
173	130	7:30 AM - 6:00 PM		Poster
174	131	7:30 AM - 6:00 PM		Poster
176	132	7:30 AM - 6:00 PM		Poster
177	133	7:30 AM - 6:00 PM		Poster
178	134	7:30 AM - 6:00 PM		Poster
179	135	7:30 AM - 6:00 PM		Poster
180	136	7:30 AM - 6:00 PM		Poster
181	137	7:30 AM - 6:00 PM		Poster
182	138	7:30 AM - 6:00 PM		Poster
183	139	7:30 AM - 6:00 PM		Poster
184	140	7:30 AM - 6:00 PM		Poster
185	141	7:30 AM - 6:00 PM		Poster
186	142	7:30 AM - 6:00 PM		Poster
187	143	7:30 AM - 6:00 PM		Poster
188	144	7:30 AM - 6:00 PM		Poster

ABSTRACT INDEX Final Program

Abstract #	Poster #	Presentation Time	Room	Format
Friday, August 20 ...continued				
189	145	7:30 AM - 6:00 PM		Poster
191	146	7:30 AM - 6:00 PM		Poster
192	147	7:30 AM - 6:00 PM		Poster
193	148	7:30 AM - 6:00 PM		Poster
194	149	7:30 AM - 6:00 PM		Poster
195	150	7:30 AM - 6:00 PM		Poster
196	151	7:30 AM - 6:00 PM		Poster
197	152	7:30 AM - 6:00 PM		Poster
198	153	7:30 AM - 6:00 PM		Poster
199	154	7:30 AM - 6:00 PM		Poster
200	155	7:30 AM - 6:00 PM		Poster
201	156	7:30 AM - 6:00 PM		Poster
202	157	7:30 AM - 6:00 PM		Poster
203	158	7:30 AM - 6:00 PM		Poster
204	159	7:30 AM - 6:00 PM		Poster
205	160	7:30 AM - 6:00 PM		Poster
206	161	7:30 AM - 6:00 PM		Poster
175	162	7:30 AM - 6:00 PM		Poster
207	163	7:30 AM - 6:00 PM		Poster
208	164	7:30 AM - 6:00 PM		Poster
209	165	7:30 AM - 6:00 PM		Poster
210	166	7:30 AM - 6:00 PM		Poster
211	167	7:30 AM - 6:00 PM		Poster

Muscles and Bones

212	168	7:30 AM - 6:00 PM		Poster
213	169	7:30 AM - 6:00 PM		Poster
214	170	7:30 AM - 6:00 PM		Poster
215	171	7:30 AM - 6:00 PM		Poster
216	172	7:30 AM - 6:00 PM		Poster

Pharmacovigilance

217	173	7:30 AM - 6:00 PM		Poster
218	174	7:30 AM - 6:00 PM		Poster
219	175	<i>Abstract Withdrawn by Author</i>		
220	176	7:30 AM - 6:00 PM		Poster
221	177	7:30 AM - 6:00 PM		Poster
222	178	7:30 AM - 6:00 PM		Poster
223	179	7:30 AM - 6:00 PM		Poster
224	180	7:30 AM - 6:00 PM		Poster
225	181	7:30 AM - 6:00 PM		Poster
226	182	7:30 AM - 6:00 PM		Poster
227	183	7:30 AM - 6:00 PM		Poster
228	184	7:30 AM - 6:00 PM		Poster

Risk Management / Communication

229	185	7:30 AM - 6:00 PM		Poster
230	186	7:30 AM - 6:00 PM		Poster
231	187	7:30 AM - 6:00 PM		Poster
232	188	<i>Abstract Withdrawn by Author</i>		
233	189	7:30 AM - 6:00 PM		Poster
234	190	7:30 AM - 6:00 PM		Poster
235	191	7:30 AM - 6:00 PM		Poster
236	192	7:30 AM - 6:00 PM		Poster

Abstract #	Poster #	Presentation Time	Room	Format
Saturday, August 21				
237		8:30 AM	Balmoral	Oral
238		8:45 AM	Balmoral	Oral
239		9:00 AM	Balmoral	Oral
240		9:15 AM	Balmoral	Oral
241		9:30 AM	Balmoral	Oral
242		9:45 AM	Balmoral	Oral
243		8:30 AM	Cambridge	Oral
244		8:45 AM	Cambridge	Oral
245		9:00 AM	Cambridge	Oral
246		9:15 AM	Cambridge	Oral
247		9:30 AM	Cambridge	Oral
190		9:45 AM	Cambridge	Oral
464		8:30 AM	Buckingham	Oral
250		8:45 AM	Buckingham	Oral
251		9:00 AM	Buckingham	Oral
252		9:15 AM	Buckingham	Oral
253		9:30 AM	Buckingham	Oral
254		9:45 AM	Buckingham	Oral
255		8:30 AM	Dukes	Oral
256		8:45 AM	Dukes	Oral
257		9:00 AM	Dukes	Oral
258		9:15 AM	Dukes	Oral
259		9:30 AM	Dukes	Oral
260		9:45 AM	Dukes	Oral
261		8:30 AM	Clarence	Oral
262		8:45 AM	Clarence	Oral
263		9:00 AM	Clarence	Oral
264		9:15 AM	Clarence	Oral
265		9:30 AM	Clarence	Oral
266		9:45 AM	Clarence	Oral
267		8:30 AM	Oxford	Oral
268		8:45 AM	Oxford	Oral
269		9:00 AM	Oxford	Oral
270		9:15 AM	Oxford	Oral
271		9:30 AM	Oxford	Oral
272		9:45 AM	Oxford	Oral
273		10:30 AM	Dukes	Oral
274		10:45 AM	Dukes	Oral
275		11:00 AM	Dukes	Oral
276		11:15 AM	Dukes	Oral
277		11:30 AM	Dukes	Oral
278		11:45 AM	Dukes	Oral
279		10:30 AM	Oxford	Oral
280		10:45 AM	Oxford	Oral
612		11:00 AM	Oxford	Oral
282		11:15 AM	Oxford	Oral
283		11:30 AM	Oxford	Oral
284		11:45 AM	Oxford	Oral
285		10:30 AM	Cambridge	Oral
286		10:45 AM	Cambridge	Oral
287		11:00 AM	Cambridge	Oral
288		11:15 AM	Cambridge	Oral
289		11:30 AM	Cambridge	Oral
290		11:45 AM	Cambridge	Oral
291		10:30 AM	Balmoral	Oral
292		10:45 AM	Balmoral	Oral
293		11:00 AM	Balmoral	Oral
294		11:15 AM	Balmoral	Oral

ABSTRACT INDEX Final Program

Abstract #	Poster #	Presentation Time	Room	Format
295		11:30 AM	Balmoral	Oral
296		11:45 AM	Balmoral	Oral
297		10:30 AM	Buckingham	Oral
298		10:45 AM	Buckingham	Oral
299		11:00 AM	Buckingham	Oral
300		11:15 AM	Buckingham	Oral
301		11:30 AM	Buckingham	Oral
302		11:45 AM	Buckingham	Oral
303		10:30 AM	Clarence	Oral
304		10:45 AM	Clarence	Oral
305		11:00 AM	Clarence	Oral
306		11:15 AM	Clarence	Oral
307		11:30 AM	Clarence	Oral
308		11:45 AM	Clarence	Oral

Edlavitch Award (Best Student Abstracts)

309		2:30 PM	Clarence	Oral
-----	--	---------	----------	------

Optimizing Global Vaccine Safety Monitoring: Lessons Learned from H1N1

310		4:00 PM	Hall 4	Sympos.
-----	--	---------	--------	---------

Matching on Propensity Scores: Good Practices and New Directions

311		4:00 PM	Balmoral	Sympos.
-----	--	---------	----------	---------

Regulatory Risk Communication Are We Getting Ahead?

312		4:00 PM	Oxford	Sympos.
-----	--	---------	--------	---------

Role of Meta-Analysis in Drug Safety: Methodological Considerations and Regulatory Implications

313		4:00 PM	Buckingham	Sympos.
-----	--	---------	------------	---------

The Panacea of Study Designs in Pharmacoepidemiology: Which One? Antipsychotics and Myocardial Infarct in the Demented Elderly Population

314		4:00 PM	Dukes	Sympos.
-----	--	---------	-------	---------

How Can Better Scientific Methods Result in Better Drug Regulation - Two Recent Case Studies

315		4:00 PM	Clarence	Sympos.
-----	--	---------	----------	---------

Evaluating Adverse Pregnancy Outcomes – A Workshop to Develop an Inventory of Methodological Issues Related to Different Approaches

780		4:00 PM	Ambassador	Sympos.
-----	--	---------	------------	---------

Poster Session B

Anti-infectives

316	1	8:00 AM - 6:00 PM		Poster
317	2	8:00 AM - 6:00 PM		Poster
318	3	8:00 AM - 6:00 PM		Poster
319	4	8:00 AM - 6:00 PM		Poster
320	5	8:00 AM - 6:00 PM		Poster
321	6	8:00 AM - 6:00 PM		Poster
322	7	8:00 AM - 6:00 PM		Poster
323	8	8:00 AM - 6:00 PM		Poster
324	9	<i>Abstract Withdrawn by Author</i>		
325	10	8:00 AM - 6:00 PM		Poster
326	11	8:00 AM - 6:00 PM		Poster

Abstract #	Poster #	Presentation Time	Room	Format
327	12	8:00 AM - 6:00 PM		Poster
328	13	<i>Abstract Withdrawn by Author</i>		
349	14	8:00 AM - 6:00 PM		Poster

Cardiovascular

329	15	8:00 AM - 6:00 PM		Poster
330	16	8:00 AM - 6:00 PM		Poster
331	17	8:00 AM - 6:00 PM		Poster
332	18	8:00 AM - 6:00 PM		Poster
333	19	8:00 AM - 6:00 PM		Poster
334	20	8:00 AM - 6:00 PM		Poster
335	21	8:00 AM - 6:00 PM		Poster
336	22	8:00 AM - 6:00 PM		Poster
337	23	8:00 AM - 6:00 PM		Poster
338	24	<i>Abstract Withdrawn by Author</i>		
339	25	8:00 AM - 6:00 PM		Poster
340	26	8:00 AM - 6:00 PM		Poster
341	27	8:00 AM - 6:00 PM		Poster
342	28	8:00 AM - 6:00 PM		Poster
343	29	8:00 AM - 6:00 PM		Poster
344	30	8:00 AM - 6:00 PM		Poster
346	31	8:00 AM - 6:00 PM		Poster
347	32	8:00 AM - 6:00 PM		Poster
348	33	8:00 AM - 6:00 PM		Poster

Classical Pharmacoepidemiology

350	34	8:00 AM - 6:00 PM		Poster
351	35	8:00 AM - 6:00 PM		Poster
352	36	8:00 AM - 6:00 PM		Poster
353	37	8:00 AM - 6:00 PM		Poster
354	38	8:00 AM - 6:00 PM		Poster

CNS

355	39	8:00 AM - 6:00 PM		Poster
356	40	8:00 AM - 6:00 PM		Poster
357	41	8:00 AM - 6:00 PM		Poster
358	42	8:00 AM - 6:00 PM		Poster
359	43	8:00 AM - 6:00 PM		Poster
360	44	8:00 AM - 6:00 PM		Poster
361	45	<i>Abstract Withdrawn by Author</i>		
649	46	8:00 AM - 6:00 PM		Poster

Drug Utilization Research/Health Services Research

362	47	8:00 AM - 6:00 PM		Poster
363	48	8:00 AM - 6:00 PM		Poster
364	49	8:00 AM - 6:00 PM		Poster
365	50	8:00 AM - 6:00 PM		Poster
366	51	8:00 AM - 6:00 PM		Poster
367	52	8:00 AM - 6:00 PM		Poster
368	53	8:00 AM - 6:00 PM		Poster
369	54	8:00 AM - 6:00 PM		Poster
370	55	8:00 AM - 6:00 PM		Poster
371	56	8:00 AM - 6:00 PM		Poster
372	57	<i>Abstract Withdrawn by Author</i>		
373	58	8:00 AM - 6:00 PM		Poster
374	59	8:00 AM - 6:00 PM		Poster
375	60	8:00 AM - 6:00 PM		Poster
376	61	8:00 AM - 6:00 PM		Poster
377	62	8:00 AM - 6:00 PM		Poster
378	63	8:00 AM - 6:00 PM		Poster
379	64	8:00 AM - 6:00 PM		Poster

ABSTRACT INDEX Final Program

Abstract #	Poster #	Presentation Time	Room	Format
Saturday, August 21 ...continued				
380	65	8:00 AM - 6:00 PM		Poster
381	66	8:00 AM - 6:00 PM		Poster
382	67	8:00 AM - 6:00 PM		Poster
383	68	8:00 AM - 6:00 PM		Poster

Gut

384	69	8:00 AM - 6:00 PM		Poster
385	70	8:00 AM - 6:00 PM		Poster
386	71	8:00 AM - 6:00 PM		Poster
387	72	8:00 AM - 6:00 PM		Poster
388	73	8:00 AM - 6:00 PM		Poster
389	74	8:00 AM - 6:00 PM		Poster
390	75	8:00 AM - 6:00 PM		Poster
391	76	8:00 AM - 6:00 PM		Poster
392	77	8:00 AM - 6:00 PM		Poster
393	78	8:00 AM - 6:00 PM		Poster
394	79	<i>Abstract Withdrawn by Author</i>		
395	80	8:00 AM - 6:00 PM		Poster
396	81	8:00 AM - 6:00 PM		Poster
397	82	8:00 AM - 6:00 PM		Poster
398	83	8:00 AM - 6:00 PM		Poster
399	84	8:00 AM - 6:00 PM		Poster

Methods

400	85	8:00 AM - 6:00 PM		Poster
401	86	<i>Abstract Withdrawn by Author</i>		
402	87	8:00 AM - 6:00 PM		Poster
403	88	8:00 AM - 6:00 PM		Poster
404	89	8:00 AM - 6:00 PM		Poster
405	90	8:00 AM - 6:00 PM		Poster
406	91	8:00 AM - 6:00 PM		Poster
407	92	8:00 AM - 6:00 PM		Poster
408	93	8:00 AM - 6:00 PM		Poster
409	94	8:00 AM - 6:00 PM		Poster
410	95	8:00 AM - 6:00 PM		Poster

Muscles and Bones

411	96	8:00 AM - 6:00 PM		Poster
412	97	8:00 AM - 6:00 PM		Poster
413	98	8:00 AM - 6:00 PM		Poster
414	99	8:00 AM - 6:00 PM		Poster
415	100	8:00 AM - 6:00 PM		Poster
416	101	8:00 AM - 6:00 PM		Poster

Other

417	102	8:00 AM - 6:00 PM		Poster
418	103	8:00 AM - 6:00 PM		Poster
419	104	8:00 AM - 6:00 PM		Poster
420	105	8:00 AM - 6:00 PM		Poster
421	106	8:00 AM - 6:00 PM		Poster

Pharmacovigilance

422	107	8:00 AM - 6:00 PM		Poster
423	108	8:00 AM - 6:00 PM		Poster
424	109	8:00 AM - 6:00 PM		Poster
425	110	8:00 AM - 6:00 PM		Poster
426	111	8:00 AM - 6:00 PM		Poster
427	112	8:00 AM - 6:00 PM		Poster
428	113	8:00 AM - 6:00 PM		Poster
429	114	8:00 AM - 6:00 PM		Poster
430	115	<i>Abstract Withdrawn by Author</i>		

Abstract #	Poster #	Presentation Time	Room	Format
Saturday, August 21 ...continued				
431	116	8:00 AM - 6:00 PM		Poster
432	117	8:00 AM - 6:00 PM		Poster
433	118	8:00 AM - 6:00 PM		Poster
434	119	8:00 AM - 6:00 PM		Poster
435	120	<i>Abstract Withdrawn by Author</i>		

Poster Walk - Biologics SIG

436	121	8:00 AM - 6:00 PM	Poster Walk	
437	122	8:00 AM - 6:00 PM	Poster Walk	
438	123	8:00 AM - 6:00 PM	Poster Walk	
439	124	8:00 AM - 6:00 PM	Poster Walk	
440	125	8:00 AM - 6:00 PM	Poster Walk	
441	126	8:00 AM - 6:00 PM	Poster Walk	
442	127	8:00 AM - 6:00 PM	Poster Walk	
443	128	8:00 AM - 6:00 PM	Poster Walk	
444	129	8:00 AM - 6:00 PM	Poster Walk	
445	130	8:00 AM - 6:00 PM	Poster Walk	
446	131	8:00 AM - 6:00 PM	Poster Walk	

Poster Walk - Comparative Effectiveness Research SIG

447	132	8:00 AM - 6:00 PM	Poster Walk	
449	133	8:00 AM - 6:00 PM	Poster Walk	
450	134	8:00 AM - 6:00 PM	Poster Walk	
451	135	8:00 AM - 6:00 PM	Poster Walk	
452	136	8:00 AM - 6:00 PM	Poster Walk	
453	137	8:00 AM - 6:00 PM	Poster Walk	
454	138	<i>Abstract Withdrawn by Author</i>		
455	139	8:00 AM - 6:00 PM	Poster Walk	
457	140	8:00 AM - 6:00 PM	Poster Walk	
458	141	8:00 AM - 6:00 PM	Poster Walk	

Poster Walk - Database SIG

459	142	8:00 AM - 6:00 PM	Poster Walk	
460	143	8:00 AM - 6:00 PM	Poster Walk	
461	144	8:00 AM - 6:00 PM	Poster Walk	
462	145	<i>Abstract Withdrawn by Author</i>		
463	146	8:00 AM - 6:00 PM	Poster Walk	
465	147	8:00 AM - 6:00 PM	Poster Walk	
466	148	8:00 AM - 6:00 PM	Poster Walk	
468	149	8:00 AM - 6:00 PM	Poster Walk	

Poster Walk - Utilization SIG

469	150	8:00 AM - 6:00 PM	Poster Walk	
470	151	8:00 AM - 6:00 PM	Poster Walk	
471	152	8:00 AM - 6:00 PM	Poster Walk	
472	153	8:00 AM - 6:00 PM	Poster Walk	
473	154	8:00 AM - 6:00 PM	Poster Walk	
474	155	8:00 AM - 6:00 PM	Poster Walk	
475	156	8:00 AM - 6:00 PM	Poster Walk	
476	157	8:00 AM - 6:00 PM	Poster Walk	
477	158	8:00 AM - 6:00 PM	Poster Walk	
478	159	8:00 AM - 6:00 PM	Poster Walk	

Poster Walk - Molecular - Epidemiology SIG

479	160	8:00 AM - 6:00 PM	Poster Walk	
480	161	8:00 AM - 6:00 PM	Poster Walk	
481	162	8:00 AM - 6:00 PM	Poster Walk	
482	163	8:00 AM - 6:00 PM	Poster Walk	
483	164	8:00 AM - 6:00 PM	Poster Walk	

ABSTRACT INDEX Final Program

Abstract #	Poster #	Presentation Time	Room	Format
Saturday, August 21 ...continued				
484	165	8:00 AM - 6:00 PM	Poster Walk	
485	166	8:00 AM - 6:00 PM	Poster Walk	
486	167	8:00 AM - 6:00 PM	Poster Walk	
487	168	8:00 AM - 6:00 PM	Poster Walk	
488	169	8:00 AM - 6:00 PM	Poster Walk	
489	170	8:00 AM - 6:00 PM	Poster Walk	
Poster Walk -Pregnancy SIG				
490	171	8:00 AM - 6:00 PM	Poster Walk	
491	172	8:00 AM - 6:00 PM	Poster Walk	
492	173	8:00 AM - 6:00 PM	Poster Walk	
493	174	8:00 AM - 6:00 PM	Poster Walk	
494	175	8:00 AM - 6:00 PM	Poster Walk	
495	176	8:00 AM - 6:00 PM	Poster Walk	
496	177	8:00 AM - 6:00 PM	Poster Walk	
497	178	8:00 AM - 6:00 PM	Poster Walk	
498	179	8:00 AM - 6:00 PM	Poster Walk	
499	180	8:00 AM - 6:00 PM	Poster Walk	

Sunday, August 22				
500		8:30 AM	Oxford	Oral
501		8:45 AM	Oxford	Oral
502		9:00 AM	Oxford	Oral
503		9:15 AM	Oxford	Oral
504		9:30 AM	Oxford	Oral
456		9:45 AM	Oxford	Oral
506		8:30 AM	Buckingham	Oral
507		8:45 AM	Buckingham	Oral
508		9:00 AM	Buckingham	Oral
509		9:15 AM	Buckingham	Oral
510		9:30 AM	Buckingham	Oral
511		9:45 AM	Buckingham	Oral
512		8:30 AM	Balmoral	Oral
513		8:45 AM	Balmoral	Oral
467		9:00 AM	Balmoral	Oral
515		9:15 AM	Balmoral	Oral
516		9:30 AM	Balmoral	Oral
517		9:45 AM	Balmoral	Oral
518		8:30 AM	Cambridge	Oral
519		8:45 AM	Cambridge	Oral
520		9:00 AM	Cambridge	Oral
521		9:15 AM	Cambridge	Oral
522		9:30 AM	Cambridge	Oral
523		9:45 AM	Cambridge	Oral
524		8:30 AM	Clarence	Oral
525		8:45 AM	Clarence	Oral
526		9:00 AM	Clarence	Oral
527		9:15 AM	Clarence	Oral
528		9:30 AM	Clarence	Oral
529		9:45 AM	Clarence	Oral
530		8:30 AM	Dukes	Oral
531		8:45 AM	Dukes	Oral
532		9:00 AM	Dukes	Oral
533		9:15 AM	Dukes	Oral
534		9:30 AM	Dukes	Oral
116		9:45 AM	Dukes	Oral
536		10:30 AM	Oxford	Oral
537		10:45 AM	Oxford	Oral

Abstract #	Poster #	Presentation Time	Room	Format
Sunday, August 22 ...continued				
538		11:00 AM	Oxford	Oral
539		11:15 AM	Oxford	Oral
540		11:30 AM	Oxford	Oral
541		11:45 AM	Oxford	Ora
542		10:30 AM	Balmoral	Oral
543		10:45 AM	Balmoral	Oral
544		11:00 AM	Balmoral	Oral
104		11:15 AM	Balmoral	Oral
448		11:30 AM	Balmoral	Oral
547		11:45 AM	Balmoral	Oral
548		10:30 AM	Cambridge	Oral
549		10:45 AM	Cambridge	Oral
550		11:00 AM	Cambridge	Oral
551		11:15 AM	Cambridge	Oral
552		11:30 AM	Cambridge	Oral
553		11:45 AM	Cambridge	Oral
554		10:30 AM	Buckingham	Oral
555		10:45 AM	Buckingham	Oral
556		11:00 AM	Buckingham	Oral
23		11:15 AM	Buckingham	Oral
558		11:30 AM	Buckingham	Oral
559		11:45 AM	Buckingham	Oral
560		10:30 AM	Dukes	Oral
561		10:45 AM	Dukes	Oral
562		11:00 AM	Dukes	Oral
563		11:15 AM	Dukes	Oral
564		11:30 AM	Dukes	Oral
565		11:45 AM	Dukes	Oral
566		10:30 AM	Clarence	Oral
567		10:45 AM	Clarence	Oral
568		11:00 AM	Clarence	Oral
569		11:15 AM	Clarence	Oral
570		11:30 AM	Clarence	Oral
571		11:45 AM	Clarence	Oral

Lessons Learned from Collaboration among EU Biologics Registries in Rheumatology

572		1:30 PM	Hall 4	Sympos.
-----	--	---------	--------	---------

The Industry-Academic Nexus: Experiences, Perspectives, and Suggestions for Enhancing Research Relationships

573		1:30 PM	Cambridge	Sympos.
-----	--	---------	-----------	---------

The Alternate Life of Regulators

574		1:30 PM	Oxford	Sympos.
-----	--	---------	--------	---------

Rare Diseases: Unmet Medical Needs, Epidemiology and Regulatory Considerations

576		1:30 PM	Dukes	Sympos.
-----	--	---------	-------	---------

Linking Administrative and Electronic Medical Record Databases Using Hybrid Probabilistic and Deterministic Techniques

577		1:30 PM	Balmoral	Sympos.
-----	--	---------	----------	---------

Challenges and Opportunities in Shaping Medical Device Epidemiology

781		1:30 PM	Buckingham	Sympos.
-----	--	---------	------------	---------

Observed vs Expected Methodologies in Vaccine Safety Surveillance

782		1:30 PM	Clarence	Sympos.
-----	--	---------	----------	---------

ABSTRACT INDEX Final Program

Abstract #	Poster #	Presentation Time	Room	Format
Sunday, August 22 ...continued				
Poster Session C				
Anti-infectives				
578	1	8:00 AM - 1:45 PM		Poster
579	2	8:00 AM - 1:45 PM		Poster
580	3	8:00 AM - 1:45 PM		Poster
581	4	8:00 AM - 1:45 PM		Poster
582	5	8:00 AM - 1:45 PM		Poster
583	6	8:00 AM - 1:45 PM		Poster
584	7	8:00 AM - 1:45 PM		Poster
Burden of Disease/Epidemiology of Illness				
585	8	8:00 AM - 1:45 PM		Poster
586	9	8:00 AM - 1:45 PM		Poster
587	10	8:00 AM - 1:45 PM		Poster
588	11	8:00 AM - 1:45 PM		Poster
589	12	8:00 AM - 1:45 PM		Poster
590	13	8:00 AM - 1:45 PM		Poster
591	14	8:00 AM - 1:45 PM		Poster
592	15	<i>Abstract Withdrawn by Author</i>		
593	16	8:00 AM - 1:45 PM		Poster
594	17	8:00 AM - 1:45 PM		Poster
595	18	8:00 AM - 1:45 PM		Poster
596	19	8:00 AM - 1:45 PM		Poster
597	20	8:00 AM - 1:45 PM		Poster
598	21	8:00 AM - 1:45 PM		Poster
599	22	8:00 AM - 1:45 PM		Poster
600	23	8:00 AM - 1:45 PM		Poster
601	24	8:00 AM - 1:45 PM		Poster
602	25	8:00 AM - 1:45 PM		Poster
603	26	8:00 AM - 1:45 PM		Poster
604	27	8:00 AM - 1:45 PM		Poster
605	28	8:00 AM - 1:45 PM		Poster
606	29	8:00 AM - 1:45 PM		Poster
607	30	8:00 AM - 1:45 PM		Poster
608	31	8:00 AM - 1:45 PM		Poster
Cancer and Immunity				
609	32	8:00 AM - 1:45 PM		Poster
610	33	8:00 AM - 1:45 PM		Poster
611	34	8:00 AM - 1:45 PM		Poster
613	35	8:00 AM - 1:45 PM		Poster
614	36	8:00 AM - 1:45 PM		Poster
615	37	8:00 AM - 1:45 PM		Poster
616	38	8:00 AM - 1:45 PM		Poster
617	39	8:00 AM - 1:45 PM		Poster
618	40	8:00 AM - 1:45 PM		Poster
619	41	8:00 AM - 1:45 PM		Poster
620	42	8:00 AM - 1:45 PM		Poster
Cardiovascular				
621	43	<i>Abstract Withdrawn by Author</i>		
622	44	8:00 AM - 1:45 PM		Poster
623	45	8:00 AM - 1:45 PM		Poster
624	46	<i>Abstract Withdrawn by Author</i>		
625	47	8:00 AM - 1:45 PM		Poster
626	48	8:00 AM - 1:45 PM		Poster
627	49	8:00 AM - 1:45 PM		Poster
628	50	8:00 AM - 1:45 PM		Poster
629	51	8:00 AM - 1:45 PM		Poster
630	52	8:00 AM - 1:45 PM		Poster

Abstract #	Poster #	Presentation Time	Room	Format
Sunday, August 22 ...continued				
631	53	8:00 AM - 1:45 PM		Poster
632	54	8:00 AM - 1:45 PM		Poster
633	55	8:00 AM - 1:45 PM		Poster
634	56	8:00 AM - 1:45 PM		Poster
635	57	8:00 AM - 1:45 PM		Poster
636	58	8:00 AM - 1:45 PM		Poster
637	59	8:00 AM - 1:45 PM		Poster
638	60	8:00 AM - 1:45 PM		Poster
639	61	8:00 AM - 1:45 PM		Poster
CNS				
640	62	8:00 AM - 1:45 PM		Poster
641	63	8:00 AM - 1:45 PM		Poster
642	64	8:00 AM - 1:45 PM		Poster
643	65	8:00 AM - 1:45 PM		Poster
644	66	8:00 AM - 1:45 PM		Poster
645	67	8:00 AM - 1:45 PM		Poster
646	68	8:00 AM - 1:45 PM		Poster
647	69	8:00 AM - 1:45 PM		Poster
648	70	8:00 AM - 1:45 PM		Poster
650	71	8:00 AM - 1:45 PM		Poster
651	72	<i>Abstract Withdrawn by Author</i>		
652	73	8:00 AM - 1:45 PM		Poster
653	74	8:00 AM - 1:45 PM		Poster
654	75	8:00 AM - 1:45 PM		Poster
655	76	8:00 AM - 1:45 PM		Poster
656	77	8:00 AM - 1:45 PM		Poster
657	78	8:00 AM - 1:45 PM		Poster
658	79	<i>Abstract Withdrawn by Author</i>		
659	80	8:00 AM - 1:45 PM		Poster
660	81	8:00 AM - 1:45 PM		Poster
661	82	8:00 AM - 1:45 PM		Poster
662	83	8:00 AM - 1:45 PM		Poster
663	84	8:00 AM - 1:45 PM		Poster
664	85	8:00 AM - 1:45 PM		Poster
665	86	8:00 AM - 1:45 PM		Poster
666	87	8:00 AM - 1:45 PM		Poster
667	88	8:00 AM - 1:45 PM		Poster
668	89	8:00 AM - 1:45 PM		Poster
669	90	8:00 AM - 1:45 PM		Poster
670	91	8:00 AM - 1:45 PM		Poster
671	92	8:00 AM - 1:45 PM		Poster
672	93	8:00 AM - 1:45 PM		Poster
673	94	8:00 AM - 1:45 PM		Poster
674	95	8:00 AM - 1:45 PM		Poster
675	96	8:00 AM - 1:45 PM		Poster
Drug Utilization Research/Health Services Research				
676	97	8:00 AM - 1:45 PM		Poster
677	98	8:00 AM - 1:45 PM		Poster
678	99	8:00 AM - 1:45 PM		Poster
679	100	8:00 AM - 1:45 PM		Poster
680	101	8:00 AM - 1:45 PM		Poster
681	102	8:00 AM - 1:45 PM		Poster
682	103	8:00 AM - 1:45 PM		Poster
683	104	8:00 AM - 1:45 PM		Poster
684	105	<i>Abstract Withdrawn by Author</i>		
685	106	8:00 AM - 1:45 PM		Poster
686	107	8:00 AM - 1:45 PM		Poster
687	108	8:00 AM - 1:45 PM		Poster

ABSTRACT INDEX Final Program

Abstract #	Poster #	Presentation Time	Room	Format
Sunday, August 22 ...continued				
688	109	8:00 AM - 1:45 PM		Poster
689	110	8:00 AM - 1:45 PM		Poster
690	111	8:00 AM - 1:45 PM		Poster
691	112	8:00 AM - 1:45 PM		Poster
692	113	8:00 AM - 1:45 PM		Poster
693	114	8:00 AM - 1:45 PM		Poster
694	115	<i>Abstract Withdrawn by Author</i>		
695	116	8:00 AM - 1:45 PM		Poster
696	117	8:00 AM - 1:45 PM		Poster
Gut				
697	118	8:00 AM - 1:45 PM		Poster
698	119	8:00 AM - 1:45 PM		Poster
699	120	8:00 AM - 1:45 PM		Poster
700	121	8:00 AM - 1:45 PM		Poster
701	122	8:00 AM - 1:45 PM		Poster
702	123	8:00 AM - 1:45 PM		Poster
703	124	8:00 AM - 1:45 PM		Poster
Medications in Pregnancy				
704	125	8:00 AM - 1:45 PM		Poster
705	126	8:00 AM - 1:45 PM		Poster
706	127	8:00 AM - 1:45 PM		Poster
707	128	8:00 AM - 1:45 PM		Poster
708	129	8:00 AM - 1:45 PM		Poster
709	130	8:00 AM - 1:45 PM		Poster
710	131	8:00 AM - 1:45 PM		Poster
711	132	8:00 AM - 1:45 PM		Poster
Methods				
712	133	8:00 AM - 1:45 PM		Poster
713	134	8:00 AM - 1:45 PM		Poster
714	135	8:00 AM - 1:45 PM		Poster
715	136	8:00 AM - 1:45 PM		Poster
716	137	8:00 AM - 1:45 PM		Poster
717	138	8:00 AM - 1:45 PM		Poster
718	139	8:00 AM - 1:45 PM		Poster
719	140	8:00 AM - 1:45 PM		Poster
720	141	8:00 AM - 1:45 PM		Poster
721	142	8:00 AM - 1:45 PM		Poster
722	143	<i>Abstract Withdrawn by Author</i>		
723	144	8:00 AM - 1:45 PM		Poster
724	145	8:00 AM - 1:45 PM		Poster
725	146	8:00 AM - 1:45 PM		Poster
726	147	8:00 AM - 1:45 PM		Poster
727	148	8:00 AM - 1:45 PM		Poster
728	149	8:00 AM - 1:45 PM		Poster
729	150	8:00 AM - 1:45 PM		Poster
730	151	8:00 AM - 1:45 PM		Poster
731	152	8:00 AM - 1:45 PM		Poster
732	153	8:00 AM - 1:45 PM		Poster
733	154	8:00 AM - 1:45 PM		Poster
734	155	8:00 AM - 1:45 PM		Poster
735	156	8:00 AM - 1:45 PM		Poster
736	157	8:00 AM - 1:45 PM		Poster
737	158	8:00 AM - 1:45 PM		Poster

Abstract #	Poster #	Presentation Time	Room	Format
Sunday, August 22 ...continued				
Muscles and Bones				
738	159	8:00 AM - 1:45 PM		Poster
739	160	8:00 AM - 1:45 PM		Poster
740	161	8:00 AM - 1:45 PM		Poster
741	162	8:00 AM - 1:45 PM		Poster
742	163	8:00 AM - 1:45 PM		Poster
743	164	8:00 AM - 1:45 PM		Poster
744	165	8:00 AM - 1:45 PM		Poster
745	166	8:00 AM - 1:45 PM		Poster
746	167	8:00 AM - 1:45 PM		Poster
747	168	8:00 AM - 1:45 PM		Poster
748	169	8:00 AM - 1:45 PM		Poster
749	170	8:00 AM - 1:45 PM		Poster
Pharmacovigilance				
750	171	8:00 AM - 1:45 PM		Poster
751	172	8:00 AM - 1:45 PM		Poster
752	173	8:00 AM - 1:45 PM		Poster
753	174	8:00 AM - 1:45 PM		Poster
754	175	8:00 AM - 1:45 PM		Poster
755	176	8:00 AM - 1:45 PM		Poster
756	177	8:00 AM - 1:45 PM		Poster
757	178	8:00 AM - 1:45 PM		Poster
758	179	8:00 AM - 1:45 PM		Poster
759	180	8:00 AM - 1:45 PM		Poster
Vaccines				
760	181	8:00 AM - 1:45 PM		Poster
761	182	8:00 AM - 1:45 PM		Poster
762	183	8:00 AM - 1:45 PM		Poster
763	184	8:00 AM - 1:45 PM		Poster
764	185	8:00 AM - 1:45 PM		Poster
765	186	8:00 AM - 1:45 PM		Poster
766	187	8:00 AM - 1:45 PM		Poster
767	188	8:00 AM - 1:45 PM		Poster
768	189	8:00 AM - 1:45 PM		Poster
769	190	8:00 AM - 1:45 PM		Poster
770	191	8:00 AM - 1:45 PM		Poster
771	192	8:00 AM - 1:45 PM		Poster
772	193	8:00 AM - 1:45 PM		Poster
773	194	8:00 AM - 1:45 PM		Poster
774	195	8:00 AM - 1:45 PM		Poster
775	196	8:00 AM - 1:45 PM		Poster
776	197	8:00 AM - 1:45 PM		Poster
777	198	8:00 AM - 1:45 PM		Poster
778	199	8:00 AM - 1:45 PM		Poster
779	200	8:00 AM - 1:45 PM		Poster

PDS Pharmacoepidemiology & Drug Safety

Official Journal of the International Society for Pharmacoepidemiology

Editor-in-Chief: Professor Brian L. Strom

Pharmacoepidemiology & Drug Safety provides an international forum for the communication and evaluation of data, methods and opinion in the discipline of pharmacoepidemiology.

- Free online access for ISPE members via the society website
- Latest Impact Factor: 2.527 (JCR® 2009)

A selection of the top-downloaded papers from the 2009 Volume (18)

- Quantitative signal detection using spontaneous ADR reporting.
A. Bate, S. J. W. Evans. Volume 18, Issue 6, Pages 427-36
- Relationship between thiazolidinedione use and cardiovascular outcomes and all-cause mortality among patients with diabetes: a time-updated propensity analysis.
Zeina A. Habib, Leonidas Tzogias, Suzanne L. Havstad, et al. Volume 18, Issue 6, Pages 437-47
- Drug-induced torsades de pointes: data mining of the public version of the FDA Adverse Event Reporting System (AERS).
Elisabetta Poluzzi, Emanuel Raschi, Ugo Moretti, et al. Volume 18, Issue 6, Pages 512-18
- Antidepressant medication use and risk of persistent pulmonary hypertension of the newborn.
Susan E. Andrade, Heather McPhillips, David Loren, et al. Volume 18, Issue 3, Pages 246-52
- Non-aspirin NSAIDs, cyclooxygenase-2 inhibitors and risk for cardiovascular events-stroke, acute myocardial infarction, and death from coronary heart disease.
Christianne L. Roumie, Neesha N. Choma, Lisa Kaltenbach, et al. Volume 18, Issue 11, Pages 1053-63



For more information on these top papers and other journal features, please visit

www.interscience.wiley.com/journal/pds

Print ISSN: 1053-8569 • Online ISSN: 1099-1557 • 2010 Volume: 19 • Frequency: Monthly

 **WILEY-BLACKWELL**

HILTON BRIGHTON METROPOLE Meeting Rooms



**26th International Conference
on Pharmacoepidemiology and
Therapeutic Risk Management**